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Abstract 
 
Apathy, a symptom reflecting motivational and self-initiation impairment, is one of the 
most common neuropsychiatric symptoms in Parkinson’s disease (PD), with an average 
estimated prevalence of 40-45%. Elevated apathy has been associated with a host of negative 
associates and consequences, including cognitive impairment, poor daily functioning, poor 
treatment compliance and illness outcome, reduced quality of life, and increased caregiver 
burden and distress. While some studies have evaluated pharmacologic approaches to the 
treatment of apathy, few studies have evaluated non-pharmacologic approaches and we have 
identified no studies that have evaluated the efficacy of non-pharmacologic treatments of apathy 
in Parkinson’s patients despite the need for such research. The purpose of the present study was 
to develop and gather pilot data on the acceptability, feasibility, and estimated efficacy of a 
primarily telephone-based, 6-week activity scheduling and monitoring intervention that 
incorporates an external cueing component to target disease-related self-generational deficits, on 
reducing levels of apathy in non-demented, highly apathetic PD patients. The project included 
three phases: (1) development of protocol materials, (2) determine ease of training 
paraprofessional interventionists, and (3) to assess feasibility, acceptability, and estimated effect 
of treatment in a one-arm uncontrolled trial. Patient apathy, depression, and quality of life 
significantly improved post-treatment and improvements in apathy and depression were 
maintained at one-month follow-up. While enrollment proved challenging, feasibility, 
acceptability, and efficacy data were strong and promising. Larger, randomized controlled trials 
are needed to investigate the efficacy of the presented intervention.   
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Introduction 
 
Parkinson’s Disease (PD) is a chronic and degenerative neurological disorder that affects 
600,000 to 1 million people in the United States alone. While motor dysfunction is most apparent 
in PD, psychiatric symptoms have been reported to occur in as many as 90% of PD patients. 
Apathy, a symptom reflecting motivational and self-initiation impairment, is one of the most 
common neuropsychiatric symptoms in PD and other disorders involving frontal-subcortical 
circuitry, with an average estimated prevalence of 40-45%. Elevated apathy has been associated 
with a host of negative consequences, including cognitive impairment, poor daily functioning, 
poor treatment compliance and illness outcome, reduced quality of life, and increased caregiver 
burden and distress. While some studies have evaluated pharmacologic approaches to the 
treatment of apathy, very few studies have evaluated non-pharmacologic approaches. Further, no 
studies have evaluated the efficacy of non-pharmacologic treatments of apathy in Parkinson’s 
patients despite the need for such research.  
The present study sought to develop and gather pilot data on the acceptability, feasibility, 
and estimated effect of a 6-week, primarily telephone delivered, activity scheduling program, 
that incorporated an external cueing component, on patient apathy and other important outcomes 
in a sample of non-demented, apathetic PD patients and their caregivers. Specifically, the 
intervention aimed to reduce elevated levels of apathy, improve patient depressive symptoms, 
daily functioning, and quality of life, and improve burden/distress in the caregivers/spouses of 
participating PD patients. 
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Parkinson’s Disease 
First described as the “shaking palsy” by James Parkinson in 1817 (Parkinson, 1817), 
Parkinson’s Disease (PD) has since become prevalent worldwide, occurring in an estimated 
600,000 to 1 million people in the United States alone with approximately 70,000 individuals 
developing PD each year (Mayeux, 2003). Most cases of PD present after the age of 50, with a 
mean age of onset at 55 to 60 years, and few cases, if any, appear after the age of 80 (Mackin, 
2000; Stern, 1993). While initially characterized by its motor dysfunction, PD is now recognized 
as a disease in which psychiatric and cognitive complications are common. Although the exact 
cause of PD remains unknown, there are several theorized causes of the disorder including toxic 
exposures (environmental, occupational, or drug induced), oxidative stress, and genetics. Most 
cases of PD are considered idiopathic, or, of unknown cause.  
 Pathophysiology. PD is a chronic, progressive neurodegenerative disorder marked by 
slow degeneration of dopamine producing neurons primarily in the pars compacta of the 
substantia nigra. The depletion of dopamine interferes largely with the nigrostriatal pathway of 
the basal ganglia, a system largely implicated in the production of movement and coordinated 
muscle control (Gibb, 1992; Tisch, Silberstein, Limousin-Dowsy, and Jahanshahi, 2004). The 
nigrostriatal pathway is one of the major dopaminergic pathways in the brain and transmits 
dopamine from the substantia nigra (i.e., “nigro-“) to the striatum (i.e., “-striatal”). It is the 
disruption of this circuit that results in the cardinal motor features of PD (i.e., tremor, rigidity, 
and bradykinesia). It is estimated that PD patients have lost at least 60-70% of their dopamine-
producing cells by the time motor symptoms appear (Fearnley and Lees, 1991).  
There is also evidence of disruption to other dopaminergic circuits (e.g., mesolimbic and 
mesocortical pathways) and other brain regions (e.g. locus ceoruleus, ventral tegmental area, 
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amygdala, raphe nuclei), resulting in noradrenergic, serotonergic, and cholinergic abnormalities 
of the basal ganglia (Lang and Lozano, 1998; Mackin, 2000). The mesolimbic dopamine 
pathway, often referred to as the “reward pathway,” transmits dopamine from the ventral 
tegmental area (VTA) of the midbrain (i.e., “meso-“) to the nucleus accumbens, ventral striatum, 
septal area, amygdala, hippocampus of the limbic system (i.e., “-limbic”), and is involved in 
pleasurable feelings of reward (i.e., hedonia), reward learning, and motivation (Tisch et al., 
2004). Decreased dopamine in the mesolimbic pathway may contribute to psychiatric symptoms 
of depression and apathy (Lieberman, 2006; Fibiger, 1984). Decreased dopamine in the 
mesocortical pathway, a third major dopamine pathway that transmits dopamine from the VTA 
(i.e., “meso-“) to the PFC (i.e., “-cortical”), underlies the executive dysfunction (e.g., set-shifting 
and verbal fluency) that is common among PD patients, as well as impairments in working 
memory, learning, and attention (e.g., Rinne et al., 2000; Floresco and Magyar, 2006). 
 Motor symptoms. The classic triad of motor signs in PD include resting tremor, rigidity, 
and bradykinesia/akinesia (Lang and Lozano, 1998). Resting tremor is the most common and 
identifiable sign of disease, with approximately 70% to 75% of cases reporting tremor as their 
initial complaint (Stern, 1993). The tremor is referred to as a resting tremor because it occurs 
when the limbs are at rest and subsides when movement is initiated voluntarily. Rigidity, or 
cogwheeling, refers to muscle stiffness that occurs and can result in muscle pain or discomfort. 
Bradykinesia refers to the slowness of voluntary movement (e.g., standing up, walking, and 
sitting down) that occurs as a result of delayed transmission signals from the brain to the muscles. 
Parkinson’s gait, characterized by a shortened stride and shuffling steps, is another common 
feature. Other primary motor symptoms include postural instability, or poor balance, and 
coordination impairment. In later stages of the disease, akinesia (lack of voluntary movement), 
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festination (more severe and abnormal gait pattern), hypophonia (decreased speech volume), 
dysarthria (speech impairment), chewing and swallowing difficulties, as well as drooling can 
occur (Mackin, 2000).  
Symptom progression varies by individual but typically progresses over a period of 10 to 
20 years (Langston, 1990). Progression can be divided into three states: early, nonfluctuating, 
and fluctuating (Manyam, 1997).  Patients in the early stage of disease generally show unilateral 
symptoms (i.e., on one side of the body) and may be monosymptomatic or have multiple mild 
symptoms that need minimal medication management or none at all. In the nonfluctuating stage, 
symptoms increase in severity but respond well to medication. Symptoms may respond to first-
line dopamine replacement therapy (i.e., single drug treatment, such as Levodopa or a dopamine 
agonist) or to a combination of medications. Once patients have reached the fluctuating stage of 
disease, medication is less effective and symptom control fluctuates. Motor fluctuations may 
include the “wearing-off effect,” in which dopamine replacement medication lasts for a 
decreasing amount of time, or the “on-off phenomenon,” in which the patient cycles between 
experiencing complete improvement of symptoms that may last for hours to experiencing no 
therapeutic effect of the medication. When patients are “On” they feel more control over their 
movement; whereas, when patients are “Off” they experience the motor and non-motor 
symptoms of the disease (Stocchi, Jenner, and Obeso, 2010). The frequency of fluctuations 
varies by individual, but can occur several times per day.   
 Neuropsychiatric symptoms. While motor dysfunction is typically the most apparent in 
PD, the disease is often conceptualized as a neuropsychiatric disease because of the high 
prevalence of cognitive and psychiatric complications. Cognitive decline affects up to 90% of 
patients (Pirozzolo, Hansch, Mortimer, Webster, and Kuskowski, 1982). In contrast, dementia 
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(i.e. severe cognitive impairment that affects daily living) is less frequent, affecting 
approximately 25% of patients, as most symptoms are subtle and do not interfere significantly 
with everyday activities (Mayeux et al., 1990; Stocchi and Brusa, 2000). The greatest area of 
cognitive difficulty for PD patients involves executive functions, mental operations involved in 
adapting to novel situations, problem solving, planning, generating new concepts and elaborating 
cognitive and behavioral responses to environmental situations (Stocchi and Brusa, 2000). Other 
characteristic cognitive changes in PD include impairment in attention, abstraction and reasoning, 
visuospatial abilities, and memory (Stocchi and Brusa, 2000). 
Psychiatric symptoms have been reported to occur in as many as 90% of PD patients 
(Starkstein, Mayberg, Leiguarda, Preziosi, and Robinson, 1992b). Apathy, depression, and 
anxiety are the most prevalent psychiatric symptoms in PD, but sleep disturbance and 
medication-induced hallucinations also occur at high rates (Aarsland et al., 2009; Jankovic J, 
2008). These hallucinations are generally visual and benign in nature (Mackin, 2000). 
Psychiatric symptoms have a significant negative impact on daily functioning, quality of life, 
cognitive functioning and caregiver burden and distress (Aarsland et al., 2007; Karlsen et al., 
2000; Shrag, Jahanshahi, and Quinn, 2000; Chen, 2004; Keranen et al., 2003), with some 
research suggesting that the negative impact of psychiatric symptoms is even greater than the 
impact of motor symptom severity (e.g., GPDS, 2002). Moreover, a multitude of studies have 
demonstrated that elevations in apathy, specifically, are associated with a host of negative 
consequences, from impaired cognitive and daily functioning to decreased treatment compliance 
and responsiveness to decreased quality of life in patients and caregivers (van Reekum, Stuss, 
and Ostrander, 2005; Onyike et al., 2007; de Vugt et al., 2003; Yeager and Hyer, 2008; Isella et 
al., 2002; Aarsland et al., 1997, 1999a; Levy et al., 1998). 
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Apathy 
Apathy is characterized by diminished motivation and initiative in three domains- goal-
directed behavior, thought, and emotion (Marin, 1991). It is one of the most common psychiatric 
symptoms in patients with neurologic disease (van Reekum, et al., 2005; Chase, 2010) and is 
associated with disruption of the brain’s frontal-striatal circuitry. Patients with lesions to, or 
diseases affecting, the frontal and/or subcortical brain structures show high rates of apathy. 
Apathy, referred to as a “negative symptom” in the schizophrenia literature, affects about half of 
patients diagnosed with schizophrenia, and is associated with reduced frontal lobe volume and 
reduced functional outcome in this population (Kiang, Christensen, Remington, and Kapur, 2003; 
Roth et al., 2004; Fearden et al., 2009). Some of the most alarming rates of apathy have been 
reported in patients with progressive supranuclear palsy and frontotemporal dementia, with 
reported prevalences of 91% in progressive supranuclear palsy and 90% in frontotemporal 
dementia (Levy, 1998). Interestingly, these patients rarely have depression alone, and much more 
often present with apathy in the absence of depression than apathy in the presence of depression. 
The overall average point prevalence of apathy is 61.4% in traumatic brain injury (van Reekum 
et al., 2005), 57.5% in Huntington’s disease (Levy, 1998; Paulsen et al., 2001), 55% in 
Alzheimer’s disease (van Reekum et al., 2005), 40 and 45% in PD (Isella et al., 2002; Starkstein 
et al., 1992a), and 33.8% in vascular dementia (van Reekum et al., 2005).  
 Apathy is not depression. While apathy may exist as a symptom of depression, in many 
cases (e.g., neurologic diseases such as Alzheimer’s disease, frontotemporal dementia, 
progressive supranuclear palsy, and PD) apathy can occur without depression or, when they are 
both present within a particular patient, they may be clinically and anatomically independent and 
dissimilar in their correlations to other signs and symptoms (Levy and Czernecki, 2006). Various 
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methods have been employed to examine the discriminability of apathy and depression as 
independent clinical phenomena. Such investigations include the evaluation of the rates and 
relationships between apathy and depression in different diagnostic groups (i.e., PD, Alzheimer’s 
disease, frontotemporal dementia, progressive supranuclear palsy, and Huntington’s disease; e.g., 
Marin, Firinciogullari, and Biedrzycki, 1994, Levy et al., 1998), the exploration of the 
differential relationship of apathy and depression with other clinical variables (i.e., stage of 
disease, cognitive impairment, and functional impairment; e.g., Landes, Sperry, and Strauss, 
2005), the evaluation of their independent associations with cognitive functioning (e.g., 
Butterfield et al, 2010; Isella et al., 2002; Kuzis et al., 1999), and examination of the differential 
effects of treatment on apathy and depression (e.g., Padala, Burke, Bhatia, and Petty, 2007; 
Weitzner, Kanfer, and Booth-Jones, 2005). While certain symptoms may be shared among 
apathy and depression (i.e., diminished interest, psychomotor retardation, fatigue/hypersomnia, 
lack of insight), several researchers have suggested that certain symptoms are unique to apathy 
(i.e., blunted affect, indifference, low social engagement, diminished initiation, poor persistence) 
and certain symptoms are unique to depression (i.e., dysphoria, suicidal ideation, self-criticism, 
feelings of guilt, pessimism, hopelessness, sleep disturbance) (Marin, Firinciogullari, and 
Biedrzycki, 1993, Marin 1990, Landes, Sperry, Strauss, and Geldmacher, 2001). 
 Defining and measuring apathy. The definition of apathy has undergone numerous 
revisions over recent years. The study of apathy as a neuropsychiatric construct in neurological 
disorders began in 1990 (Marin, 1990; Burns, Folstein, Brandt, and Folstein, 1990; Robinson and 
Starkstein, 1990). While the term apathy (derived from the Greek term pathos, meaning passions) 
is conventionally described as the absence or lack of emotion, feeling, interest, or concern 
(Marin, 1990, 1991), Marin considered this description as lacking due to its failure to address a 
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variety of other features present in the apathetic patient. Marin (1991) proposed to define apathy 
as a distinct psychiatric syndrome characterized by motivational impairment, which he described 
as “a deficit in the direction, intensity and persistence of goal-directed behavior.” Marin 
proposed that the clinical expression of apathy can be classified into three domains: (1) reduced 
goal-directed behavior (i.e., lack of productivity, effort, initiative, or perseverance; compliance 
or dependence on others to structure activity; diminished socialization or recreation), (2) reduced 
goal-directed cognition (i.e., lack of interests or lack of interest in learning new things or in 
having new experiences; lack of plans or goals; lack of concern about one’s personal problems; 
lack of value attributed to goal-related domains), and (3) reduced emotional concomitants of 
goal-directed behaviors (i.e., flattened affect; reduced emotional intensity; lack of emotional 
responsiveness to positive or negative events) (Marin, 1991). His conceptualization of apathy as 
a disorder of drive and motivation slightly differs from other conceptualizations of apathy as 
more of a disorder of feeling and/or emotion expression (Starkstein and Leentjens, 2008). In fact, 
opinions differ on whether or not the criteria for apathy should include an emotional dimension. 
More recently, the definition has evolved to highlight that initiation, or the lack of it, is 
key to the definition, whether that lack of initiation is in relation to behavioral action, cognitive 
action, or emotional action (Stuss, van Reekum, and Murphy, 2000; van Reekum et al., 2005; 
Levy and Czernecki, 2006). Stuss et al. (2000) defined apathy as “an absence of responsiveness 
to stimuli as demonstrated by a lack of self-initiated action.” Levy and Czernecki (2006) viewed 
apathy as “a quantitative reduction of self-generated voluntary and purposeful behaviors” as 
compared to previous behavior, despite an unchanging environment or physical constraints. 
In addition to experiencing symptoms of apathy, several neuropsychiatric disorders seem 
to produce a syndrome of apathy, in which a pattern of apathy symptoms from each domain are 
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present but this motivational impairment is not secondary to cognitive or intellectual impairment 
(i.e., dementia), emotional distress (i.e., major depression), or diminished level of consciousness 
(i.e, delirium or drowsiness) (Marin, 1990, 1991). Due to the fact that the many patients 
experience apathy in the presence of depression or dementia, Starkstein (2000) adapted 
diagnostic criteria for the diagnosis of apathy syndrome that allowed for the diagnosis of apathy 
even in the presence of depression or dementia, assuming that the symptoms cause significant 
distress or impairment in social, occupational, or other important areas of functioning. 
Discussion continues regarding a consensus as to the appropriate gold standard for 
clinical diagnosis of apathy. Some suggest that apathy is underrepresented in psychiatric 
classification systems, like the ICD-10 and DSM-IV. After all, apathy is not referenced in the 
ICD-10 (World Health Organization, 1993) and is only mentioned specifically in relation to four 
disorders of the DSM-IV (American Psychological Association, 1994), with no inclusion of the 
term “apathy” in the DSM-IV glossary. Discussion regarding differential diagnosis and whether 
apathy should appear as a stand-alone disorder in the DSM-V has begun (Stephenson, 2005). If 
not included as a stand-alone disorder, potential improvements of the status of apathy, including 
clarifying the definition, adding apathy to the glossary of the DSM, or creating a reference to 
help direct clinicians to the range of disorders commonly associated with apathy, are being 
considered by DSM-IV Editor (Stephenson, 2005). 
The majority of clinical research studies thus far have defined apathy by using self-, 
relative- and clinician-rating scales that examine the presence, frequency, and severity of apathy 
symptoms.  Psychometric support exists for a number of such instruments and cut-off scores 
have been established for several to indicate the presence of clinically significant apathy. Such 
cut-off scores have been determined based on either the presence of a bimodal distribution or the 
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identification of scores that indicate apathy levels of 1 ½ – 2 standard deviations above the mean 
of healthy elderly controls. For instance, the Apathy Evaluation Scale (AES), developed by Marin 
and colleagues in 1991, was one of the first instruments created to assess apathy in neurologic 
populations and continues to be widely used due to its strong psychometric support (Marin and 
Wilkozs, 2005). The AES consists of 18 items, scored on a four-point Likert scale, that assess 
emotional, cognitive, and behavioral symptoms of apathy. It has been validated for the 
assessment of apathy in patients with PD, Alzheimer’s disease and other dementias, stroke, and 
major depression (Pluck and Brown, 2002; Marin, Biedrzycki, and Firinciogullari, 1991) and has 
demonstrated adequate reliability and validity for use in PD (Pluck and Brown, 2002; Starkstein 
et al., 1992a). The cut-off score of 38 on the self-rating scale, a score indicative of apathy levels 
of 1 ½ standard deviations above the mean for healthy elderly controls, has been established to 
indicate significantly elevated apathy (Marin et al., 1994). The AES was later modified and 
abridged to the 14-item Apathy Scale (AS) (Starkstein et al., 1992a). Similar instruments include 
the Frontal Systems Behavior Scale (FrSBe; Grace and Malloy, 2001), formerly known as the 
Frontal Lobe Personality Scale (FLOPS; Grace, Stout, and Malloy, 1999) and the Lille Apathy 
Rating Scale (LARS; Sockeel et al., 2006). Shorter screening instruments include the apathy item 
(item 7) of the Neuropsychiatric Inventory (NPI; Cummings et al., 1994), which assesses the 
frequency and severity of apathy; the Apathy Inventory (AI; Robert and colleagues, 2002), a 
three item apathy scale that measures the frequency and severity of emotional blunting, lack of 
initiative, and lack of interest; and item 4 (assessing apathy) on Part I of the Unified Parkinson’s 
Disease Rating Scale (UPDRS). For the purposes of the present study, the assessment of apathy 
will focus on apathy symptom severity based on number and severity of apathy symptoms using 
the AES, and a cut-off score will be utilized to identify patients with elevated apathy.  
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 Pathogenesis of apathy. Understanding the neural basis of apathy requires an 
understanding of motivation circuitry, including the neuroanatomical regions and neurochemical 
pathways involved. Core neural structures underlying motivation, or self-generated voluntary 
goal-directed behavior, include the ventral tegmental area (VTA), nucleus accumbens (NA), 
striatum (i.e., caudate and putamen), ventral pallidum (VP), medial dorsal nucleus of the 
thalamus (MD), and the anterior cingulate (AC) of the prefrontal cortex (PFC). Some of these 
functionally connected regions, specifically the AC, NA, VP, and MD, have been referred to as 
the cortico-striatal-pallidal-thalamic circuit (Kalivas, Churchill, and Klitenick, 1993; Marin, 
1996) and damage to regions along this pathway has been strongly associated with disorders of 
motivation (i.e., apathy, abulia, akinetic mutism) (Marin, 2005).  
The VTA, NA, and VP have been referred to as the “core circuit” of motivation (Kalivas 
et al., 1993; Marin, 1996), although some consider the AC as part of the “core circuit” due to its 
interconnection with the other components and its important role in motivational aspects of 
decision-making (Marin, 1996). The medial portions receive input from the amygdala, 
hippocampus, and AC, therefore modulating information in the “core circuit” and influencing 
response selection based on current environmental stimuli, previously reinforcing stimuli, and 
the organism’s drive state (Marin and Wilkosz, 2005; Marin, 1996). The lateral portions of the 
“core circuit” project via the MD to the motor cortex, basal ganglia, pedunculopontine nucleus, 
reticulospinal tract, and AC. The translation of motivation into action depends on the information 
flow through this “core circuit” and damage to the circuit results in impairment to the initiation 
and maintenance of goal-directed behavior and locomotor action (Kalivas et al., 1993; Pierce and 
Kalivas, 1997).  
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These structures communicate largely by way of dopamine, a neurotransmitter that 
travels through the brain via the dopaminergic pathways (i.e., nigrostriatal, mesolimbic, and 
mesocortical) described previously. Dopamine is centrally involved in motivation and reward 
processing as well as in the personality characteristic of novelty/sensation seeking (Marin and 
Wilkosz, 2005). Interference to the structures of this motivational circuit, whether from localized 
damage (e.g., frontal lobe, amygdalar, hippocampal, or basal ganglia lesions) or disease (e.g., 
PD, Alzheimer’s disease, or Huntington’s disease), often results in the presence of apathy or 
more severe motivational impairment (i.e., athymhormia, abulia, akinetic mutism).  
Levy and Dubois (2006) maintain that apathy can stem from different neuroanatomical 
mechanisms. Emotional apathy appears to be related to lesions of the orbital-medial PFC or 
related basal ganglia subregions; cognitive apathy appears to be related to lesions of the 
dorsolateral PFC and related basal ganglia subregions; and apathy that reflects a problem with 
“auto-activation” appears to be related to lesions to the associative and limbic regions of the 
internal globus pallidus.  
 Negative consequences of apathy. Apathy has been associated with a host of negative 
consequences for a variety of patients and their caregivers, from impairments in cognition and 
daily functioning to poor illness outcome and increased likelihood for institutionalization to 
increased caregiver distress. Several studies have shown an association between apathy and 
cognitive impairment (Starkstein et al., 1992a; Levy, 1998; Aarsland et al., 1999b; Kuzis et al., 
1999; Isella et al., 2002; Pluck and Brown, 2002; Feil, Razani, Boone, and Lesser, 2003; 
Starkstein, Ingram, Garau, and Mizrahi, 2005; Butterfield et al., 2010). In a sample of 
Alzheimer’s disease patients, those with apathy had significantly more severe cognitive deficits 
than those without apathy (Starkstein et al., 2005). In a sample of PD patients, apathy predicted 
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impairments in executive functioning and memory over and above that of depression (Butterfield 
et al., 2010). Findings from several studies (e.g., Isella et al., 2002; Pluck and Brown, 2002) 
suggest that apathy is more strongly associated with cognitive impairment than is depression, and 
many authors encourage careful examination of symptoms in order to identify the presence of 
dysphoria (e.g., sad mood, guilt, pessimism) versus apathy (e.g., decreased initiation, decreased 
persistence) (Boyle and Malloy, 2004).  
Some studies suggest that apathy may, in fact, be a predictor of dementia. In a sample of 
apathetic and non-apathetic Alzheimer’s disease patients, patients in the apathetic group showed 
a significantly faster rate of cognitive decline than those in the non-apathetic group over time 
(Doody et al., 1995).  One longitudinal study (Copeland et al., 2003) showed that individuals 
with MCI who exhibited the symptom of “passivity” (i.e., apathy) had higher rates of conversion 
to dementia over a three year time period. Another longitudinal study (Starkstein et al., 2006) 
found that, in patients with mild and moderate dementia, apathy was associated with faster 
declines in cognitive ability and daily functioning. A recent study demonstrated that MCI 
patients with apathy showed significantly higher rates of conversion to dementia (60%) than 
MCI patients classified as either depressed (7.9%) or depressed and apathetic (19%) (Vicini 
Chilovi et al., 2009). Even when controlling for age, functional status, and cognitive status, the 
presence of apathy in MCI patients was a positive risk factor for conversion to dementia, 
whereas depression was not. Results of these studies suggest that apathy may be a marker of 
conversion from MCI to dementia. Onyike et al. (2007) suggests that apathy in elderly 
individuals may be considered a “predementia phenotype,” stating that “dementia may begin 
with apathy.”  
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In terms of the negative association between apathy and functional abilities, Starkstein 
and colleagues (1993) found that patients in a stroke inpatient unit with apathy and depression 
were more functionally impaired than patients with apathy alone, but that apathetic patients 
without depression were more functionally impaired than those with depression alone and were 
more functionally impaired than those with neither apathy nor depression. In another study 
(Resnick et al., 1998), apathy level upon admission into a geriatric inpatient rehabilitation unit 
(i.e., reasons for admission included hip fracture, stroke, etc.) was the second strongest 
independent predictor of daily functioning at discharge. Apathetic Alzheimer’s disease patients 
scored lower on activities of daily living than non-apathetic Alzheimer’s disease patients, 
regardless of whether these patients had comorbid depression (Starkstein et al., 2001). Hamilton 
et al. (2003) observed that apathy independently predicted functional disability in patients with 
Huntington’s disease. Further, high apathy has been predictive of poor daily functioning and 
poor quality of life in normal elderly (Cahn et al., 2000), dementia populations (Norton et al., 
2001; Samus et al., 2005), PD (Pluck and Brown, 2002; Weintraub, Moberg, Duda, Katz, and 
Stern, 2004), and patients with subcortical infarcts (Reyes et al., 2009), and has been predictive 
of poor adaptive, social, and occupational functioning in patients diagnosed with schizophrenia 
(Velligan, Ritch, Sui, DiCocco, and Huntzinger, 2002).  
Elevated apathy can also result in poorer treatment compliance, social and community 
participation, and even illness outcome. Resnick et al. (1998) found that geriatric patients in an 
inpatient rehabilitation unit participated less in rehabilitation when apathy was high, while those 
with low levels of apathy participated in rehabilitation more frequently. In a sample of TBI 
patients, those with elevated apathy showed unsatisfactory integration into home and community 
activities (Cattelani et al., 2008). Mayo and colleagues (2009) found that even minor apathy was 
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strongly and negatively associated with recovery of social and community participation post-
stroke, and apathy had a significant negative effect on physical function and general health over 
the first twelve months post stroke (Mayo, Fellows, Scott, Cameron, and Wood-Dauphinee, 
2009). In a sample of schizophrenic patients, apathy was independently related to poor functional 
outcome, poor treatment compliance, and low treatment benefit (Kiang, Christensen, Remington, 
and Kapur, 2003). Tattan and Creed (2001) observed that apathy also was more common in 
schizophrenic patients who were noncompliant with their medication than in those who 
demonstrated medication compliance.  
Studies have shown that caregiver distress is associated with ratings of patient apathy at 
all levels of disease severity (Kaufer et al., 1998; Boyle and Malloy, 2004; Aarsland et al., 2007). 
When patients display a reduction in goal-directed behavior and initiative, spouses and 
caregivers often carry the burden of assuming responsibilities of the patient or constantly having 
to prompt the patients to engage in necessary activities. This might include the caregiver having 
to remind the patient of the day’s agenda, having to prompt the patient to take his/her 
medications, pay bills, get dressed, or do necessary household chores. In addition, caregivers 
may feel somewhat isolated if the patient is failing to initiate conversation, is generally less 
interested in social interaction. Spouses may become discouraged that they have become the sole 
member of the household to plan and initiate couples activities, such as vacations or day trips. 
Caregivers sometimes become frustrated with the patient and may misinterpret the patient’s lack 
of initiative as laziness or contempt. Hence, apathy can contribute to caregiver stress whether or 
not it is of concern to the patient him/herself.  
 Treating apathy. Due to the many negative impacts of apathy for patients and 
caregivers, identifying effective treatments to attenuate apathy is of increasing interest. There are 
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no medications approved for the specific treatment of apathy (Chase, 2010). Surprisingly few 
studies have conducted methodologically sound randomized controlled trials (RCT) to 
investigate the efficacy of pharmacologic or behavioral treatments on reducing apathy. Of the 
few that have been conducted, most have assessed apathy secondarily rather than as a primary 
outcome variable. Behavioral strategies are often preferred by individuals preferring to defer 
pharmacologic treatment. In addition, some studies suggest that behavioral strategies provide an 
added benefit when combined with pharmacologic treatment in patients with anxiety or mood 
disorders (Pampallona, Bollini, Tibaldi, Kupelnick, and Munizza, 2004; Mavissakalian, 1990). 
To date, many more treatment studies have focused on the use of medications as compared to the 
use of behavioral strategies on reducing elevated apathy in patients. Notably, most 
pharmacologic treatment studies have targeted dementia populations with dopaminergic agents 
or acetylcholinesterase inhibitors or schizophrenic patients with atypical antipsychotics (Chase, 
2010).  
Pharmacologic Treatments. Apathy and amotivation have been associated with 
neurochemical abnormalities, most notably deficient dopamine signaling (Guimaraes, Levy, 
Teixeria, Beato, and Caramelli, 2008). Dopamine has been considered the principle 
neurotransmitter of goal-directed behavior and motivation (Duffy and Kant, 1997). It has been 
suggested that the reduction of dopamine seen with advancing age might explain the increase in 
passivity and amotivation that is seen in healthy elderly individuals (Shulman, 2000). In addition, 
PD patients score lower on novelty-seeking than age-matched and disability-matched controls, 
attributed to the known disease-related dopamine deficiency (Menza, Forman, Goldstein, and 
Golde, 1990; Menza, Golbe, Cody, and Forman, 1993). For this reason, several studies have 
attempted to treat apathy using medications that enhance the neurotransmission of dopamine and 
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other catecholamines (i.e., epinephrine, norepinephrine), which all derive from the same 
precursors and are part of a shared synthesis pathway.  
Methylphenidate is considered one of the most promising pharmacologic agents for 
future research on the treatment of apathy (van Reekum et al., 2005) and many studies have 
evaluated its effect on apathy in patients with PD, demented elderly, and major depressive 
disorder (Padala et al., 2007; Keenan et al., 2005; Chatterjee and Fahn, 2002; Jansen et al., 2001). 
Methylphenidate is a dopamine reuptake inhibitor that blocks the dopamine transporter and 
stimulates the release of dopamine and norepinephrine into the synapse, resulting in an overall 
increase of dopamine in the synapse (Volkow et al., 1998, 2001). The results of one small RCT 
(n = 13), one open-label study, and three case reports suggest that methylphenidate is effective in 
improving apathy in neurodegenerative diseases (Drijgers, Aalten, Winogrodzka, Verhey, and 
Leentjens, 2009). Other catecholamine agonists, including levodopa (L-Dopa), dopamine 
agonists, amantadine, and selegiline, have also demonstrated a positive effect on apathy in select 
cases of PD, traumatic brain injury, stroke, and depression (Roth, Flashman, and McAllister, 
2007; Marin, Fogel, Hawkins, Duffy, and Krupp, 1995; Czernecki et al., 2002; van Reekum et 
al., 1995; Kraus and Maki, 1997; Newburn and Newburn, 2005). Atypical antipsychotics (e.g., 
resperidone, olanzapine, clozapine), which target the dopamine system, have also proven 
effective in reducing the negative symptoms of schizophrenia, which resemble the symptoms of 
apathy (van Reekum et al., 2005). According to a review of apathy treatment studies (van 
Reekum et al., 2005), five out of six RCTs (with a total N of 3,182 patients) showed a decrease 
in negative symptoms as a result of atypical antipsychotic medication.  
 In addition, cholinergic and serotonergic pathways also play a modulatory role in 
motivation (Shulman et al., 2000) and may effectively reduce apathy in certain cases. A recent 
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review, conducted by Drijgers and colleagues (2009), examined several pharmacologic treatment 
studies conducted in neurodegenerative disease populations (e.g., Alzheimer’s disease, PD,  
Lewy body dementia, frontotemporal dementia, vascular dementia). These authors concluded 
that, given that the majority of these studies lacked sufficient information to calculate effect sizes 
or to determine the clinical relevance of the effects, the overall efficacy of cholinesterase 
inhibitors to treat apathy is inconclusive and firm conclusions can not be drawn.  
Non-pharmacologic Treatments. There is increasing interest in the identification of non-
pharmacologic treatments, as many patients wish to avoid dependence on an increased number of 
daily medications. Non-pharmacologic interventions have also shown an added benefit when 
used in conjunction with medical treatment (Pampallona et al., 2004; Mavissakalian, 1990). Such 
interventions provide tools and strategies to be used by patients and their spouses or caregivers to 
increase patient independence, patient/caregiver well-being and quality of life, and to reduce 
caregiver burden. Surprisingly few studies have investigated non-pharmacologic methods of 
treating elevated apathy, and all of the existing behavioral studies have been conducted with 
dementia patients. We are unaware of any studies that have yet investigated non-pharmacologic 
treatment approaches to reducing apathy in PD patients. Activity therapy, cognitive-
communication therapy, emotion-oriented care, multisensory stimulation, and psychomotor 
therapy are behavioral approaches that have been investigated for the treatment of apathy in 
demented patients with neurodegenerative disease (i.e., mostly Alzheimer’s disease) (Roth, 
Flashman, and McAllister, 2007). These will be outlined here.  
Politis et al. (2004) conducted a RCT that investigated the impact of a 4-week activity-
based intervention on apathy in mixed dementia patients (i.e., diagnosed using the DSM-IV) 
living in long-term care. Thirty-six patients were randomized to either a kit-based activity 
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therapy group or a time-and-attention control group. Activity therapy consisted of mental 
stimulation activities that were provided in a standardized, structured manner. Sessions lasted 
thirty minutes and occurred at a frequency of three times per week. At each session, patients 
chose from a selection of kit-based activities (i.e., geography, fun foods, farm animals, 
vegetables, and musical instruments). Each activity contained questions related to the activity 
topic. Each question served as a prompt for reflection and discussion. Many questions were 
similar to trivia questions and required the participant to discuss past experiences as they related 
to the topic. Participants of the control group spent the same amount of time in sessions. Rather 
than a structured interaction, however, these sessions were unstructured and consisted of 
participant-led discussions on the participant’s discussion topic (i.e., past history, interests) or 
activity (i.e., puzzles, artwork, reading) of choice.  
Results of the study revealed a statistically significant reduction in apathy, as rated using 
the NPI, along with improved quality of life and a reduced need for cueing in non-study 
activities for individuals in both groups two weeks post-treatment. However, there was no 
significant difference between groups. These results suggest that an activity-based mental 
stimulation intervention improves dementia patients’ level of apathy, quality of life, and need for 
cueing, but not any more benefit than one-on-one attention. The improvement in both groups 
may be explained by seemingly similar quality of engagement with activities and with the 
interventionist.  
Chapman et al. (2004) evaluated the effect of an 8-week cognitive-communication 
therapy on apathy in patients with mild to moderate Alzheimer’s disease. Fifty-four participants 
were included in the study and were assigned to one of two groups: cognitive-communication 
therapy plus donepezil or donepezil alone. The therapy consisted of twelve hours of therapy over 
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a period of eight weeks and incorporated participant-led discussions, conversations about the 
patient’s life history, psychoeducation about Alzheimer’s disease, and homework assignments. 
Results revealed a trend for decreased apathy, as measured using the NPI, in the combined 
treatment group versus the medication-only group even after a twelve month follow-up. 
Other studies have investigated the effect of validation/integrated emotion-oriented care 
on apathy in dementia patients (Verkaik, van Weert, and Francke, 2005; Finnema et al, 1998, 
2000; Droes et al., 1999; Schrijnemaekers, van Rossum E, van Heusden MJT, and 
Widdershoven, 2002). This type of care seeks to restore feelings of self-worth and reduce levels 
of stress by validating the patient’s emotional ties to his/her previous life experiences (APA, 
1997). It may also incorporate other methods of emotion-oriented care, such as supportive 
psychotherapy or gentle care, which aims to provide an atmosphere of safety, comfort, and 
closeness for the patients (Verkaik et al., 2005; Buijssen, 1991). Results of a review (Verkaik et 
al., 2005), which evaluated the effect of validation/integrated emotion-oriented care on apathy in 
patients with dementia and included one multi-site RCT of 146 patients with a “usual care” 
control group, revealed no significant effect of this treatment on apathy.  
Kragt et al. (1997) examined the effect of multisensory stimulation (MSS), or Snoezelen, 
therapy on apathy in sixteen dementia patients. MSS was initially developed as a leisure center 
that provided sensory stimulation in a number of modalities (i.e., auditory, visual, and tactile) to 
patients with severe learning disabilities. The treatment has been tried in dementia populations in 
an effort to counter the lack of stimulation that often occurs with these patients due to their 
severe cognitive impairment and their inability to engage in many tasks. In this study, patients 
were placed in a controlled environment in which auditory, visual, and/or tactile sensory 
stimulation was provided. MSS therapy was compared to a usual care control condition. Results 
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revealed reduced apathy over a three-day evaluation period. Baker et al. (2003) evaluated the 
effect of MSS on behavior, mood, and cognition in a multi-national RCT of 136 dementia 
patients assigned to a MSS therapy or an activity group. Each patient participated in eight thirty-
minute sessions over a period of four weeks. Results suggested that MSS and activity therapies 
had little effect on behavior, mood, or cognition immediately post-treatment or at follow-up. 
Apathy, as measured by five items of the Behaviour Rating Scale of the Clifton Assessment 
Procedures for the Elderly (Pattie and Gilleard, 1979) did improve somewhat but only in patients 
with more severe dementia who were assigned to MSS therapy. 
In another RCT design, Hopman-Rock et al. (1999) evaluated the effect of Psychomotor 
therapy versus a control condition on apathy in 92 elderly patients with cognitive impairment. 
Psychomotor therapy consisted of 15 sessions over a period of approximately 8 weeks and 
involved participation in a variety of physical activities, sports, and games, as well as relaxation 
training. No significant change in apathy was observed. 
There is limited evidence available from which to determine whether non-pharmacologic 
treatments may be effective for attenuating apathy in patients with dementia, although some 
studies have shown promising results. No studies, however, have investigated such treatments in 
PD patients despite that rates of elevated apathy are significantly greater in even non-demented 
PD patients as compared to age-matched controls (Zgaljardic et al., 2007; Onyike et al., 2007) 
and despite its negative consequences on patients and caregivers (van Reekum et al., 2005; 
Onyike et al., 2007).  
Apathy in PD 
PD is a classic example of a subcortical disorder in which apathy is a well-recognized 
feature (Isella et al., 2002; Pluck and Brown, 2002; Aarsland et al., 1999b; Starkstein et al., 1993; 
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Marsden and Parkes, 1977). “Clinical” apathy (i.e., identified by a cut-off score established from 
a bimodal distribution of apathy or indicating a level that is 1 ½ standard deviations above the 
mean of healthy elderly controls) has been identified in approximately 40% to 45% of PD 
patients (Isella et al., 2002; Starkstein et al., 1992a), compared to 6.8% in healthy older adults 
(Onyike et al., 2007), with apathetic syndromes (i.e., not secondary to depression, delirium, or 
dementia) present in about 12% of PD patients (Starkstein et al., 1992a).  
The origin of apathy in PD is unclear, however, there exist several hypotheses. First, 
apathy appears to be a result of neurological disturbance rather than a result of psychosocial 
limitations of physical disability. Apathy does not correlate with severity of disease. In addition, 
Pluck and Brown (2002) demonstrated that, while PD and osteoarthritis are similarly chronic, 
progressive conditions that cause considerable disability, “clinical” apathy (as determined by a 
previously established cut-off score of 38 on the AES; Marin et al., 1994) was found in 37.8% of 
PD patients, but no evidence of “clinical” apathy (i.e., 0%) was present in osteoarthritic patients. 
Apathy may be a result of disruption to any one or more of the many pathways and 
regions affected in PD, including dopaminergic, cholinergic, noradrenergic, or serotoninergic 
pathways, or the affect of cortical lesions in associative cortices (Levy and Czernecki, 2006). It is 
hypothesized that the hallmark dopamine depletion of PD may contribute (Levy and Dubois, 
2006). Czernecki et al. (2002) demonstrated that apathy fluctuated between “off” and “on” states 
in PD patients, suggesting that apathy is at least partly dependent on dopamine. In other words, 
the reduction of dopamine in the dopaminergic pathways (e.g., mesocortical, mesolimbic) may 
ultimately interrupt normal reward processing, goal-directed behavior, and initiation. However, 
apathy is present in PD even in relatively early stages of the disease, when the dopamine 
mesocortico/limbic pathways are relatively spared (Levy and Czernecki, 2006). In addition, tasks 
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assessing reward sensitivity and changes in reward contingencies have been found to not be 
impaired in PD patients even when tested in the “off” state (Levy and Czernecki, 2006). Further, 
apathy can be unresponsive to dopaminergic treatment and remains an important problem in 
many PD patients receiving dopaminergic treatment (Sockeel et al., 2006).  
Another hypothesis to explain apathy in PD suggests that apathy (along with several 
other signs of the disease) may result from the inability of the basal ganglia to adequately 
identify and separate relevant signals to be sent to the prefrontal cortex (Filion and Tremblay, 
1991; Tremblay, Filion, and Bedard, 1989; Tremblay and Filion, 1989). In other words, the 
signal to noise ratio is diminished and relevant signals are clouded. Levy and Czernecki (2006) 
suggest that this may contribute to apathy by making it difficult for output structures (i.e., 
prefrontal cortex) to disambiguate the relevant signal, causing problems in decision making and 
resulting in aborted or delayed responses. 
The negative consequences of apathy that have been presented in this paper extend to 
non-demented PD patients. Several studies have shown an association between apathy and 
cognitive impairment in non-demented PD patients, even when controlling for the influence of 
depression (Starkstein et al., 1992a; Aarsland et al., 1999; Isella et al., 2002; Pluck and Brown, 
2002; Butterfield et al., 2010). In PD, apathy has been reported to impede the treatment of motor 
disability, lead to increased disability, poor daily functioning (i.e., ADLs), and a diminished 
quality of life (Pluck and Brown, 2002; Weintraub et al., 2004; Barbas, 2006). Authors have 
urged the pursuit of treatment for apathy for non-demented PD patients as quality of life in this 
population and their carers may be stabilized or enhanced with early detection and treatment of 
elevated apathy (Zgaljardic et al., 2007). 
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A Proposed Intervention for Apathy in PD 
Given that apathy reflects amotivation evidenced by a decrease in goal-directed behavior, 
and considering the positive of behavioral activation therapies for improving activity level and 
mood in depression as well as the positive results of activity engagement therapies in some 
studies on decreasing apathy in dementia patients, we hypothesize that a treatment aimed at 
increasing goal-setting and activity identification and engagement, such as those components 
utilized in Behavior Activation Therapy (BAT; Lewinsohn, 1975), will benefit the apathetic 
patient and their spouses or caregivers. Activity planning, scheduling, and monitoring provides 
an external structure that is favorable for PD patients, while facilitating self-management skills 
and patient independence.  To provide added external support, we propose to incorporate an 
external cueing component to the intervention, which will consist of regular reminder call 
prompts. Further, this intervention will exist as a primarily telephone-based intervention in an 
effort to reduce cost while addressing several common barriers to treatment that are important to 
consider when working with patients diagnosed with PD. Telephone treatment delivery reduces 
travel and waiting time, allows for more flexible scheduling, makes treatment available to 
individuals with transportation problems and those who live far from the treatment center, and 
may improve rates of participation and adherence (Simon, Ludman, Tutty, Operskalski, and Von 
Korff, 2004).  
 Treatment Rationale.  
 Behavioral Activation Therapy and Activity Scheduling. Behavioral Activation Therapy 
(BAT) is a treatment initially developed as a treatment for depression (Lewinsohn, 1975) and 
emerged following a component analysis of Cognitive-Behavioral Therapy (CBT; Jacobsen et 
al., 1997) in which researchers concluded that the cognitive aspect of CBT added little to the 
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treatment of depression relative to the behavioral component. Depression, from a behavioral 
perspective, is maintained by environmental circumstances that reinforce and perpetuate 
depressive behavior, and by a lack of environmental circumstances to reinforce healthy behavior. 
Therefore, the goal of BAT for treating depression is to eliminate factors that reinforce depressed 
behavior and to increase activities that positively reinforce engagement in healthy behaviors. It 
involves an assessment of factors that may be maintaining depressive behavior, assessment of 
current activity engagement, construction of an activity hierarchy to plan pleasurable activities 
for the coming weeks, and regular monitoring of engagement in these planned activities. 
Interventionists, family members (if involved), and the depressed individual themselves are to 
provide positive reinforcement when pleasurable activities are engaged in.  
Lejuez, Hopko, and Hopko (2001) developed a Brief Behavioral Activation Treatment 
for Depression (BATD). BATD begins with a baseline evaluation of depressive symptoms, 
baseline daily monitoring of occurring activity engagement, and a functional evaluation of 
whether one’s environment is supportive of healthy versus depressive behavior. This is followed 
by guided identification of potential activities, selection of 15 target activities that range from 
easy to difficult, and graded monitoring of activity engagement. Finally, subjects are to schedule 
rewards for themselves for achieving weekly goals. This gives the subject something to look 
forward to and provides a source of motivation for engaging in activities and for completing the 
monitoring logs. This proposed study utilized the general structure as well as specific elements 
of BATD to target apathy in non-demented PD patients. Specific BAT-derived elements included 
in our treatment protocol included (1) baseline assessment of the target outcome variable (i.e., 
apathy) and level of activity engagement, (2) weekly evaluation and monitoring of activities, (3) 
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identifying activities, (4) creating an activity hierarchy, (5) charting progress using existing 
activity logs, and (6) planning rewards for meeting goals.  
Goal Setting and Self-Regulation. As Locke and Latham (1991, 2002) and others have 
avowed, goal setting is a cornerstone of motivation and has a considerable impact on directing 
and organizing behavior. Goals can stimulate goal-directed behavior and cognition by enhancing 
effort and persistence, providing direction, and motivating strategy development due to the 
identification of discrepancy between the present state and the ideal/goal state (Bandura, 1991; 
Locke and Latham, 1991, 2002). The most important features of effective goal setting include 
goal specificity, goal difficulty, goal commitment, and feedback (Bandura, 1991; Bandura and 
Cervone, 1983; Locke and Latham, 1991, 2002). People with specific goals demonstrate greater 
on-task attention and strategic planning (e.g., who, what, when, where, why?). Such specificity 
also increases the likelihood of goal attainment. Effective goals must also be difficult but, 
importantly, attainable. Goals that are too easy fail to motivate the individual. Goals that are 
considered unattainable due to practical inability to attain (e.g., physical or cognitive inability), 
however, are discouraging. These goals are less likely to result in the feeling of competence; 
hence, the individual is less likely to put forth effort toward an unattainable goal. Further, 
individuals are more likely to be motivated by goals to which they are committed. Individuals 
often feel committed to goals that are self-set, as opposed to goals that are assigned to them. 
However, individuals can become committed even to goals that are assigned to them. Finally, the 
provision of feedback is essential in maintaining motivation. Individuals who receive feedback 
on their performance show more effortful performance than those that do not receive feedback 
(Bandura, 1991; Bandura and Cervone, 1983). Without such feedback, we are unable to 
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determine how well or how poorly we are performing and are unable to determine whether 
changes need to be made or new strategies adopted.  
Another factor of goal setting that enhances motivation is the use of implementation 
intentions. Implementation intentions are plans that help individuals to (a) initiate, or get started 
toward, goal attainment, and (b) prepare themselves for potential set-backs that may interfere 
with goal attainment (Gollwitzer and Sheeran, 2006). They are effective in initiative goal striving 
and in enhancing persistence in the face of interference (Gollwitzer and Sheeran, 2006). Planning 
when, where, and how one will begin working toward a goal can trigger the desired behavior 
when that time and place are present. For example, one individual may have the goal of 
incorporating exercise into their daily routine. To help them to initiate engagement toward this 
goal, they may decide that they will begin exercising on Monday morning at 8am. Identifying a 
specific time and location increases the likelihood that the behavior will, in fact, be triggered. 
Ideally, when 8am on Monday morning comes around, the individual is triggered to perform the 
planned behavior. Determining a routine (e.g., “I will go for a 1 mile walk every weekday 
morning at 8am”) also makes it more likely that these conscious intentions will become more 
automatic over time, which makes the goal less vulnerable to distraction (Franken, 2007).  
Implementation intentions also prepare one for potential interferences, or set-backs. It is 
advantageous for an individual to contemplate potential interferences and plan their response to 
that interference ahead of time using an if-then frame. For example, “In an effort to prevent 
distraction from my goal, if I receive a phone call within 15 minutes prior to my scheduled walk, 
then I will not answer the phone call.” 
Self-generational deficits and the use of external cueing in PD. Internally-regulated 
self-generation is a well-studied, key feature of PD that manifests in several domains. These 
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deficits are a direct result of the disruption to the basal ganglia that occurs in the development 
and advancement of PD; the basal ganglia plays an important role in internally guided self-
generation (Marsden, 1982). The common motor impairments of bradykinesia (slowness of 
movement) and akinesia (inability or delay in initiating movement) are especially evident when 
patients attempt to self-initiate behavior (vs. acting in response to an external cue). Interestingly, 
these impairments in self-initiation are remedied by external cues.  
External sensory cues (e.g., visual, auditory, and cutaneous) have been used repeatedly in 
the rehabilitation of motor deficits, such as gait, in PD (Rubinstein, Giladi, and Hausdorf, 2002; 
Lim et al., 2005; Nieuwboer, Rochester, and Jones, 2008). Both single training sessions and 
extended training (i.e., 3-6 weeks) using external cueing have resulted in improved gait (i.e., 
walking speed, step length), balance, and transfers (Hausdorff et al., 2007; Morris, Iansek, 
Matyas, and Summers, 1996; Rochester et al., 2010; Nieuwboer et al., 2007; Mak and Hui-Chan, 
2008; Sidaway, Anderson, Danielson, Martin, and Smith, 2006). Spatial cues, such as the 
presence of lines placed perpendicular to the walking path, have resulted in increased stride 
length and gait velocity in PD patients (Martin, 1967). The provision of auditory cues, such as 
the use of a metronome, has improved gait velocity and cadence (Thaut et al., 1996). Cutaneous 
cues, provided using electrical stimulation on the hand or earlobe, have shown to improve the 
timing and kinematics (i.e., force production, velocity of movement) of gait initiation in PD 
patients (Burleigh-Jacobs, Horak, Nutt, and Obeso, 1997). External cues have even been shown 
to improve the initiation and structure of eye movements in PD patients (Winograd-Gurvich et 
al., 2004).  
In addition to aiding motor performance, several studies have demonstrated that many 
cognitive performance deficits in PD can be remedied by the use of external cues. It is well-
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known that PD patients (and others with lesions to the basal ganglia) display a cognitive inertia 
that is demonstrated by deficits in executive cognitive tasks that involve self-generation, such as 
those involving set-shifting, planning, or the self-generation of cognitive strategies, rules, or 
verbal fluency (Levy, 2007). Several studies have demonstrated that PD patients perform poorly 
on tasks when cues are absent, but that performance improves with the use of external cues (e.g., 
Buytenhuijs et al., 1994; Brown and Marsden, 1988; Taylor, Saint-Cyr, and Lang, 1986, 1990; 
Breen, 1993). For instance, Brown and Marsden (1988) demonstrated that PD patients performed 
poorly on executive functioning tasks in which the patients had to rely on their own internal cues 
or strategies and on tasks that required self-directed task specific planning, but demonstrated 
intact performance when external cueing or external stimulus control was provided. Control 
subjects, however, performed equally well on the task regardless of whether external cues were 
provided or not. Similar, PD patients show impairment on tasks of attention that require internal 
control, but perform well when external control is provided (Brown and Marsden, 1990).  
On memory tasks, PD patients perform more poorly than age-matched, healthy control 
subjects on free recall, however, their performance improves to normal on recognition tasks (e.g., 
Weiermann, Stephan, Kaelin-Lang, and Meier, 2010; Breen, 1993). In other words, while PD 
patients have difficulty retrieving items that were previously encoded, they are able to retrieve 
these items when they are provided with an external cue. Buytenhuijs and colleagues (1994) 
investigated the differential influence of explicit versus implicit cues on memory performance in 
PD patients. The authors used the California Verbal Learning Test (Delis, Kramer, Kaplan, and 
Ober, 1987), a verbal memory test comprised of a list of several words from four semantic 
categories. Subjects were not made explicitly aware of the semantic organization of the items; 
therefore, the semantic relationship of the items was considered an implicit cue that must be 
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generated by the subject to help them in recalling the items learned. Subjects that recalled items 
in the order that the experimenter read them were said to be guided by explicit cues external to 
the subject. In this study, PD subjects recalled items in a serial fashion, reflecting a more 
externally imposed strategy, whereas control subjects recalled items in semantic clusters, a result 
of an internally generated strategy. A follow-up study demonstrated that when PD patients are 
made aware of semantic clustering- in other words, when semantic clustering is externally 
provided as an explicit strategy- their memory recall improves (van Spaendonck et al., 1996).  
This suggests that PD patients use this recall strategy when prompted but do not initiate the use 
of the strategy on their own. Kritikos et al. (1995) has suggested that explicit cues improve 
performance in PD patients by replacing internally generated cues that are defective as a result of 
basal ganglia disruption.   
In summary, several studies have demonstrated that the use of external cues can 
compensate for the reduction in self-generation ability in PD patients resulting from disruption to 
the basal ganglia and frontal-subcortical circuitry. The present intervention was designed to 
address this hallmark self-initiation deficit (1) by supplying external sources of cueing and (2) by 
increasing engagement in pleasurable activities through providing increased structure and 
planning. The intervention was designed to reduce reliance on spouses or caregivers and to 
increase independence in the PD patient.  
Purpose of the Proposed Study 
The purpose of the present study was to develop and gather pilot data on the 
acceptability, feasibility, and estimated effectiveness of a 6-week activity scheduling and 
monitoring intervention, that incorporated an external cueing component to target disease-related 
self-generational deficits, on reducing levels of apathy in non-demented, highly apathetic PD 
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patients. Secondly, this study sought to investigate whether this intervention improved patient 
depression, daily functioning, and quality of life, and whether it effectively improved burden, 
distress, relationship satisfaction and quality of life in patients’ caregivers/spouses.  
To our knowledge, clinical trials investigating the effect of non-pharmacologic 
interventions on motivational deficits have not been conducted with non-demented PD patients 
despite the known negative effects of apathy on patients and their caregivers. Given that non-
demented PD patients are still largely cognitively intact and may be at a point in their disease 
where maintaining their independence remains important to them, a non-pharmacologic 
treatment that improves existing apathy while decreasing reliance on their spouse or caregiver 
may be a treatment of choice for these individuals. As suggested by Zgaljardic et al. (2007), 
quality of life in this population may be stabilized or enhanced with early detection and treatment 
of elevated apathy.  
Due to the time and expense that goes into conducting full RCTs, it is prudent for 
researchers to first conduct preparatory studies that assess whether a new treatment protocol 
holds promise for effective change. While internal validity of this study would be stronger with 
the addition of a randomized attention control group and larger sample size, a relatively recent 
shift in the approach to intervention research emphasizes a stage model that highlights the 
importance of feasibility and early phase studies in developing a foundation for future efficacy 
and effectiveness trials with new interventions in new populations (see Waskow, 1984; Onken, 
Blaine, and Battjes, 1997; Rounsaville and Carroll, 2001; van Teijlingen and Hundley, 2001; 
Kazdin, 2003; Robey, 2004). Completing a Phase One study within a three-stage model of 
intervention (Rounsaville and Carroll, 2001) not only helps the researcher to understand 
recruitment and retention challenges, acceptability of the program by the patient population 
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recruited, and the feasibility of implementing a larger randomized controlled trial before putting 
resources into such a study, but also has the potential to convince funding bodies that a larger 
study is feasible and worth funding (van Teijlingen and Hundley, 2001). Collection of pilot data 
will also allow us to estimate effect sizes of the intervention.  
Given that this study is a pre-experimental design, treatment implementation/fidelity 
methods were enacted as recommended by Lichstein’s Treatment Implementation model (Burgio 
et al., 2001) in order to ensure that the treatment was delivered adequately by interventions, 
received by participants as intended, and enacted by participants in their day-to-day lives as 
intended. Select strategies were implemented to improve these factors, such as the development 
of a treatment manual and use of an adherence checklist to guide uniform protocol delivery, 
didactic instruction and role plays during training and monitoring of new interventionists to 
ensure competency of treatment delivery, use of a planning meeting with the participant and the 
provision of a participant workbook to help with adequate treatment receipt, documentation of 
weekly activity engagement by both participants and interventionists to verify treatment receipt 
and enactment, and encouragement of participants’ performance of skills as well as the provision 
of feedback during weekly phone contacts to improve treatment enactment. 
Specific Aims. The current study had three specific aims:  
Aim 1: Develop the Parkinson’s Active Living (PAL) program protocol and materials to 
promote uniform treatment delivery. The structure and elements from an existing behavioral 
treatment, the Brief Behavioral Activation Treatment for Depression (Lejuez et al., 2001), were 
used as a foundation from which a manual for use by PAL interventionists was developed that 
outlines the PAL protocol. A workbook was be created for use by PD participants in the program 
that provides psychoeducation on apathy in PD, a description of the six week program, and 
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forms for their use in identifying activities and monitoring activity engagement over the course 
of the program. 
Aim 2: Determine feasibility or ease of training new interventionists. Competency of 
program delivery was determined by interventionists’ protocol adherence during role plays and 
during implementation of the protocol with patient participants. Adherence was calculated as a 
percentage using protocol adherence checklists created by the P.I..  
Aim 3: Conduct a single-group study to obtain preliminary data feasibility of the PAL 
protocol for this population, to identify any additional logistical problems which might occur 
using the proposed methods, and to determine a within-subject effect by evaluating effect sizes. 
A one-arm, uncontrolled exploratory trial was conducted. Feasibility was investigated by 
calculation of attrition rates. Acceptability was investigated by examining satisfaction ratings 
provided by PD participants. Effect of treatment was determined by comparing pre-intervention 
and post-intervention ratings of our primary (i.e., apathy) and secondary (i.e., patient depression, 
patient quality of life, patient daily functioning, spousal burden) outcome variables. Correlations 
were also examined to determine correlates to response to treatment. The methods and results for 
each of the three aims will be described separately and in detail below.  
Aim 1: Development of Parkinson’s Active Living (PAL) Protocol and Materials 
Method 
In order to promote uniform treatment delivery, two documents were developed to 
facilitate treatment delivery of the PAL program: (1) a manual for use by interventionists, or 
Program Coaches, that outlines the treatment protocol and (2) a workbook for use by PD 
participants in the program.  
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The manual was modeled after the Brief Behavioral Activation Treatment for Depression 
(BATD), developed by Lejuez, Hopko, and Hopko (2001) for the treatment of depression. Lejuez 
et al. (2001) provided several forms for activity and reward planning and monitoring that were 
adapted for use with PD patients within the current program. These forms were used to guide 
goal-setting and to provide an external structure for PD participants. Of note, this intervention 
was developed with the consideration of key features unique to PD patients, including an added 
external cueing component (i.e., automated phone call reminders to engage in planned activities 
several times weekly) to target the disease specific self-generation/self-initiation deficits, 
optional involvement of the spouse/caregiver during the training session to provide caregivers 
with psychoeducation about motivational deficits as well as tools and strategies to supplement 
and reinforce the individual treatment sessions, and the provision of material in both verbal and 
written form to facilitate learning and memory retention. This intervention was developed as a 
primarily telephone-based intervention to overcome potential barriers to treatment. 
The PAL Program Coach Manual and the PAL Participant Workbook were developed by 
the P.I. with the help of two research assistants. The manual and workbook were reviewed by 
graduate students and research assistants in the P.I.’s clinical neuropsychology research lab. 
Once revisions were made based on this feedback, a focus group was organized consisting of PD 
patients and spouses. Participants were mailed a copy of the participant workbook prior to the 
meeting for their review. 
The focus group was led by two research assistants, one who served as the primary 
moderator and one who served as an assistant to the moderator. Both were familiar with the 
program protocol and had been involved in the development of the manual and participant 
workbook. Research assistants were selected to serve as focus group moderators, rather than the 
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P.I., in order to increase the possibility of open, uncensored feedback from focus group 
participants. Designing and Conducting Focus Group Interviews (Krueger, 2002) was used to 
provide a basic structure, participant rules for the focus group, and guidance for the moderators. 
Following recommendations from Kruger (2002), the focus group consisted of six individuals 
(four PD patients and two spouses/caregivers of PD patients). Participants were seated at a 
conference table to enhance communication amongst participants. The meeting was initiated 
with a standard introduction that included a welcome and introduction of moderator and assistant, 
overview of the topic (e.g., purpose of the meeting, explanation of what the results will be used 
for, explanation of why participants of the group were selected), explanation of ground rules (e.g., 
no right/wrong answers, listen respectfully despite disagreement, talk to each other when 
appropriate). Participants were asked a list of questions, including general open-ended questions 
and pointed questions. Notes were taken by the assistant to the moderator throughout the meeting 
to record participant opinions and feedback to guide revisions. 
Results 
The focus group meeting lasted one and a half hours. Results of the meeting showed that 
participants expected the program to be feasible within a PD population, clear to understand and 
follow, and attainable. The patient workbook was judged to be readable and appropriate. 
Voluntary participation was deemed adequate. Suggested changes included reducing the number 
of goals to five, allowing flexible use of the iPing system (mild concerns that it may be 
obnoxious, although most participants did not express concern over this system), using the term 
“program” rather than “intervention”, explaining the term “apathy” to avoid negative connotation, 
and emphasizing the difference between initiating an activity and persisting to complete an 
activity during psychoeducation at the Planning Session. Feedback resulted in minor changes to 
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the protocol, the manual, and the participant workbook. The final PAL Program Coach Manual 
and PAL Participant Workbook are may be available by contacting the author. A brief outline of 
each is provided below.  
 PAL Program Coach manual. 
Section 1: Copy of the Participant Workbook. A copy of the PAL Participant Workbook 
is provided in this section.  
Section 2: Instructions for each session. This section provides step-by-step instruction 
for the initial Planning Session and the six telephone sessions and includes a list of goals for the 
session, materials needed, and a script for Program Coaches to follow.  
Section 3: How to set-up iPing. This section provides a description of the online iPing 
reminder call system as well as instructions for how to set up reminder calls for each participant. 
Computer screen-shots are provided for ease of training and use.  
Section 4: Important readings. This section includes relevant articles that may be of use 
for Program Coaches in helping them understand Parkinson’s disease, apathy, and other relevant 
topics.  
Section 5: Extra forms. This section includes a copy of all forms used during the 
Planning Session for easy access for Program Coaches.  
 Participant Workbook. 
Part 1: Introduction. This section provides a brief introduction to the PAL program, 
including a description of the program’s purpose, a definition of apathy, a brief summary of the 
program, and a brief description of the role of their Program Coach.  
Part 2: Program Rationale. This section provides more information on the definition and 
prevalence of apathy in Parkinson’s disease, the potential influence of apathy on patients and 
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caregivers, the purpose of the program, and a theoretical rationale. The theoretical rationale 
includes an explanation of behavioral activation for the treatment of depression (Lejuez et al., 
2001), goal-setting theory (Locke and Latham, 1991, 2002), implementation intentions 
(Gollwitzer and Sheeran, 2006), and PD self-generational deficits that can be aided through the 
use of external structure and cueing, in order to support the use of activity scheduling in the 
protocol.  
Part 3: Program Overview. This section provides a brief overview of the program 
timeline and participants responsibilities. 
Part 4: Step-by-Step Guide. This section provides a more detailed description of the 
timeline and participant responsibilities at each segment. Baseline evaluation, details of the 
Planning Session, and information on how to document activity accomplishments and how to 
report this information to the Program Coach are described.   
Aim 2: Feasibility of Training Interventionists 
Method  
Four undergraduate research assistants were trained as interventionists to determine the 
ease at which this intervention could be learned and uniformly delivered by new interventionists 
(referred to as Program Coaches). Each interventionist attended three training sessions that 
included review of the program background, protocol, and materials and a series of role plays in 
which interventionists were able to display competence in proper treatment delivery. During the 
first training session, the P.I. guided trainees through a review of the program manual, forms, and 
assessment measures; they learned to administer baseline evaluations; and, received readings on 
apathy in PD, goal-setting theory, implementation intentions, and research on the benefits of 
external cueing in PD. The duration of the first session was approximately two hours. In the 
38 
 
second training session, trainees engaged in role plays. First, the P.I. modeled the role of the 
interventionist while the trainee acted as the study participant. The duration of the second session 
was approximately two hours. Next, trainees were encouraged to practice with each other, taking 
turns playing the role of interventionist and study participant. Finally, competence was assessed 
during a third session in a role play with the P.I., with the trainee acting as the interventionist and 
the P.I. acting as the client. The duration of the third session was approximately two hours.  
Four newly trained interventionists were able to display an average of 97% adherence 
(94% for Planning Sessions, 100% for Phone Sessions) according to an adherence checklist (see 
Appendix) during a mock session role play with the P.I. at the end of training (see Table 1). They 
were able to demonstrate an understanding of goal-setting, the implementation intention process, 
and the use of activity scheduling and monitoring forms; show proficiency in the administration 
of the treatment protocol; and, demonstrate the ability to troubleshoot potential problems that 
participants or their caregivers may have during treatment participation.  
 
Table 1 
Summary of adherence ratings for newly trained interventionists during mock role play at the 
end of training 
 Adherence during 
role play of Planning 
Session 
Adherence during 
role play of Phone 
Session 
Overall adherence 
score 
Trainee 1 95% 100% 98% 
Trainee 2 100% 100% 100% 
Trainee 3 92% 100% 96% 
Trainee 4 90% 100% 95% 
Average 
adherence 
94% 100% 97% 
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 Due to initial difficulty identifying eligible participants in the Tampa Bay area where 
interventionists were trained and resided, slow recruitment speed, and brief time commitments of 
the trained interventionists, the P.I. ultimately served as the interventionist for 85% of the study 
participants. Three of the newly trained interventionists ran 1-2 participants each (15% of the 
total sample). To evaluate uniformity of treatment delivery through the duration of the study for 
this 15% of participants, these sessions were audio-taped and tapes were reviewed by the P.I. and 
assessed for adherence to the protocol using the training checklist. Adherence during these 
sessions ranged from 93% - 100%, with an average of 99% overall (96% for Planning Sessions 
and 100% for weekly phone sessions).  
Aim 3: Phase One Exploratory Study 
Method 
 Participants and procedure. 34 PD patients and 27 spouses/family members of PD 
patients were enrolled to participate in this study. Inclusion criteria included diagnosis of 
idiopathic PD, no history of other neurodegenerative disease, no current psychotic disturbance, 
AES ≥ 35, and MMSE ≥ 24. Individuals diagnosed with PD were initially recruited from the 
University of South Florida (USF) Parkinson’s Disease Center of Excellence and from monthly 
PD support groups in the Tampa Bay area. Due to difficulty identifying eligible participants, 
recruitment was expanded to include the University of Florida’s (UF) Center for Movement 
Disorders and Neurorestoration and PD support group meetings in Gainesville, The Villages, and 
Orlando.  
 To provide detail on recruitment method and challenges faced during the recruitment 
process, a detailed account of the recruitment process is provided here and presented in Figure 1.  
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Figure 1. Recruitment diagram 
 
 
300 names obtained from USF, 
UF, and support groups 
Approx. 150 unable to be reached 
- No phone number 
- Incorrect phone number 
- No answer 
Reached approx. 150 patients 
Excluded (n=17) 
- Suspected dementia or other movement 
disorder diagnosis (e.g., Parkinsonism, 
Supranuclear Palsy)  
Declined participation (n=40) 
- Not interested 
- Too busy currently 
- Live too far away 
93 patients interested in participating 
Excluded due to AES score <35 (n=66) 
25 enrolled in study via USF, UF, 
and support groups 
6 discontinued treatment 
- Discontinued immediately following 
Planning Session (n=2) 
- Discontinued 2-4 weeks after Planning 
Session (n=4) 
9 more enrolled via MJ Fox Trial 
Finder 
Unable to use data due to failure to return 
post-test questionnaires (n=1) 
Data analyzed for 27 patients 
- Total enrollment, n=34 
- Completed intervention, n=28 
- Returned pre- and post-intervention data, n=27 
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Given that all calls were not recorded, the numbers here may underestimate exact values but 
provide an idea of the process. Review of available call logs revealed that of approximately 300 
participant names received from the PD Center of Excellence at USF, patient databases at UF, 
and support groups, approximately 150 were able to be reached. Of these, 17 were excluded 
because of suspected dementia or other movement disorder diagnosis (e.g., Progressive 
Supranuclear Palsy, Lewy Body Dementia) and another 40 declined participation due to being 
busy, ill, living too far away, or not believing they were experiencing symptoms of apathy. Of 
the remaining 93 participants, 66 individuals were interested in participating but failed screening 
due to an AES score that was below the 35 point cut-off. Of these, 25 participants enrolled in our 
study and 19 completed all six weeks of the study.   
 Finally, a new resource intended to connect researchers with individuals diagnosed with 
Parkinson’s disease who are interested in participating in research, the Michael J. Fox Trial 
Finder website, was discovered and utilized. This new resource proved to be the most efficient 
recruitment source. Hundreds of emails were sent out to PD patient members of the site whose 
city of residence was within 60 miles from Tampa, Gainesville, or Orlando. The exact number of 
responders from this recruitment method is unclear as they were directed to an online survey in 
the mass email. Nine individuals recruited from this method participated in our study within a 12 
week period, one of whom did not return post-test questionnaires. Due to attrition (which is 
discussed in detail later), 27 PD patients and 23 spouses/family members were included in final 
analyses.  
 Each study participant was asked if they would like to identify a spouse or a close family 
member to serve as an optional informant. Informants were asked to complete questionnaires but 
were not required to attend the Planning Session. Informants who chose to attend the Planning 
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Session were involved in the psychoeducational portion of the session but were encouraged to be 
observers during goal setting rather than active participants. Responsibilities of the informants 
were limited to completing questionnaires at the three time points.   
PD patients were asked to complete the AES, an 18-item self-report that assesses apathy 
severity, as a first phase of screening. A score of 35 or higher (reflecting a score of greater than 
1.0 standard deviation above the mean for healthy elderly controls) was considered indicative of 
elevated apathy in the present study (Marin et al., 1994). Individuals with elevated levels of 
apathy underwent a second phase screening process. Patients who endorsed current hallucinatory 
disturbance or severe global cognitive deficit (i.e., MMSE-II < 24) were excluded from further 
participation.  
Intervention procedure details are presented in the Program Coach manual. To 
summarize, participants attended one in-person session (Planning Session) lasting about 2 to 2 ½ 
hours. Participants were first consented and expectations of participation were discussed. They 
then completed baseline assessments to assess global cognitive functioning (i.e., MMSE), a 
verbal fluency evaluation (i.e., letter and category fluency), and an interview to assess apathy 
symptomatology (i.e., LARS). Patients were guided through discussion of life areas and asked 
whether they perceived a need for improvement in each life domain, such as relationships with 
family, friends, or romantic partner, spirituality, physical and emotional health, recreational 
enjoyment, education or career pursuits, household projects needing to be initiated or completed. 
Based on this discussion, five goals were selected to be targeted during the six week intervention 
period. Each activity was planned for specific days and times during the week. Participants left 
the Planning Session with a calendar for each week of the program that outlined when each 
activity was to be completed. At the end of each week, the Program Coach conducted a phone 
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session with each patient, during which participants reported the number of activity goals 
accomplished the previous week, discussed problems with attaining planned goals, and reviewed 
the goals planned for the upcoming week.  Participants were allowed to make adjustments to 
their plan for the upcoming week if determined that their initial plan was no longer realistic or 
feasible. Phone sessions lasted 10 to 20 minutes. 
Outcome measures were mailed to participants at three time points: pre-intervention, 
post-intervention, and at one-month follow-up. Pre-intervention baseline evaluations were 
completed up to one week prior to the Planning Session (first session, completed in-person). 
Post-intervention evaluations were completed within one week after participants completed the 
sixth and final week of the intervention. One month follow-up evaluations were completed one 
month after the sixth and final week of the intervention. Participants were told that the one-
month follow-up questionnaire packet was optional to reduce perceived demand of participation. 
A timeline of activities is presented below (See Figure 2).  
 
  
Figure 2. Program Timeline 
44 
 
 Baseline Measures. PD patients were administered the following measures at baseline, 
at the beginning of their Planning Session: 
Mini Mental State Exam – Second Edition: Standard Version (MMSE-II). The MMSE-
II:SV (Folstein, Folstein, White & Messer, 2012) was administered to patient participants at 
baseline only as a screener for suspected dementia. The MMSE-II is a revised version of the 
original MMSE (Folstein, Folstein, & McHugh, 1975) with problematic items replaced and 
select tasks modified to adjust difficulty level. Overall difficulty level as well as structure and 
scoring of the original MMSE remain, allowing the MMSE-2 and MMSE scores to be 
comparable. Brief version items, totaling 30 points as in the original MMSE, were used in this 
study. Each item assesses one of the following domains: orientation to time, orientation to place, 
registration, attention, recall, naming, repetition, comprehension, reading, writing, and drawing. 
Patients scoring less than 24 (Folstein et al., 1975) were excluded from the study to avoid 
confounds of significant cognitive impairment, which may affect patients’ ability to validly 
complete self-report measures. The MMSE-II has been found to be reliable and valid in 
assessing global cognitive status (Folstein et al., 2012). 
Letter Fluency and Animal Naming. Letter Fluency and Animal Naming of the 
Controlled Oral Word Association test (COWA; Spreen & Strauss, 1991) were administered to 
patient participants who speak English as a first language at baseline only. They were 
administered to assess phonemic and category verbal fluency, indices of executive cognitive 
function, for the purpose of sample descriptives and to determine whether they impact response 
to treatment.  
Lille Apathy Rating Scale (LARS). The LARS (Sockeel et al., 2006) was administered to 
patient participants at baseline only for the purpose of better understanding the types of apathy 
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that patients experience and evaluating whether these specifics impact response to treatment. The 
LARS is a 33-item structured interview that assesses apathy in nine domains: reduction in 
everyday productivity, lack of interest, lack of initiative, extinction of novelty seeking and 
motivation, blunting of emotional responses, lack of concern, poor social life, and social 
awareness. The interview is based on the conceptual principles proposed by Marin et al (1991) 
and Stuss et al. (2000). Items 1-3 are coded on a five-point Likert scale and remaining items are 
coded as binary (yes/no) responses. A global apathy score as well as nine domain scores can be 
calculated. In a PD sample, the LARS was reported to have good concurrent validity (r = 0.75 - 
0.87), split- half reliability (r = 0.73-0.80), and inter-rater reliable were strong (r = 0.98), and 
sensitivity and specificity were high (0.89 and 0.92, respectively) (Sockeel et al., 2006; Zahodne 
et al., 2009).  
Outcome Measures. The following self-report measures were completed by patients at 
baseline, post-intervention, and at one-month follow-up.  
Primary Measure. 
 Apathy Evaluation Scale (AES). The AES-S (Marin, 1991) is an 18-item self-rating scale 
that was developed to assess apathetic symptoms within behavioral, cognitive, and emotional 
domains and was selected as the primary outcome measure for this study. A sample of healthy 
control participants scored an average of 28.1 points (SD = 6.4) on the self-rating form of this 
test. Traditionally, 38 has been used as a cut-off score to represent clinically significant apathy 
given that this score reflects apathy 1 ½ SD above the mean of healthy elderly controls. We used 
a cut-off of 35 points, reflecting a score greater than 1.0 SD above the mean in order to include a 
wider sample of patients endorsing problems in this domain. The AES has been used in a number 
of clinical groups, including PD, and has been found to have good construct and internal 
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consistency validity ( = 0.86) (Marin et al., 1991). In a sample of PD patients, convergence 
between self-rated and clinician-rated apathy was strong (r = 0.74) as was test-retest reliability 
( = 0.85) (Pluck and Brown, 2002). Sensitivity to change has not been formally evaluated but 
some evidence of it exists from its use in a studies of the impact of methylphenidate and of deep 
brain stimulation on apathy (Leentjens et al., 2008).  
Secondary Measures. 
Geriatric Depression Scale (GDS). The GDS (Yesavage et al., 1983) is a 30-item self-
report instrument designed to identify depression in elderly individuals. The scale excludes 
somatic symptoms of depression that are common in the elderly. Respondents must select “yes” 
or “no” in response to each item, reflecting how they have felt over the past week. A normative 
sample of healthy elderly individuals scored a mean of 5.75 (SD = 4.34) on the GDS (Yesavage 
et al., 1983). Scores classify patients in the ranges of normal (score of 0 – 10), mild depression 
(score of 11 – 19), or severe depression (score of 20 – 30). In a PD population, the test has well-
established internal consistency ( = 0.92, split-half r = 0.91) and good discriminability between 
depressed and non-depressed PD patients (i.e., sensitivity, positive and negative predictive 
values = 0.79 – 0.85 for cut-off score of 13/14) (Ertan, Ertan, Kiziltan, and Uyguçgil, 2005). 
Unified Parkinson’s Disease Rating Scale (UPDRS, Part II). The Activities of Daily 
Living section of the UPDRS (Part II) (Fahn and Elton, 1987) was administered to assess self-
reported daily functioning. This section of the UPDRS contains 13 items assessing different areas 
of daily functioning (i.e., speech, salivation, swallowing, handwriting, cutting food, dressing, 
hygiene, turning in bed, falling, freezing, walking, tremor, sensory complaints) using a five point 
Likert scale (i.e., 0-4), with higher scores indicating greater impairment.  
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Parkinson’s Disease Quality of Life Scale (PDQ-39). The PDQ-39 (Peto et. al, 1995) was 
used to assess overall and eight disease-specific quality of life domains: Activities of Daily 
Living (ADLs), Communication, Social, Cognition, Emotion, Stigma, Discomfort, and Mobility. 
The PDQ-39 was developed specifically for use with PD patients. This scale includes 39 items 
on a 5 point Likert scale (“Never” to “Always”). Dimension scores are converted into a scale 
from 0 (perfect health as assessed) to 100 (worse health as assessed). Studies have demonstrated 
that the PDQ-39 has strong global reliability and variable subscale reliability (internal 
consistency: Global PDQ,  = 0.94; 4/8 subscales,  = 0.43-0.93; temporal stability of scales, r = 
0.76-0.90). Convergent validity between the PDQ-39 and PDQL was strong particularly for 
summary indices (r = -0.91; subscales, r = -0.31-0.81) and group comparisons support content 
validity (Marinus, Ramaker, van Hilten, & Stiggelbout, 2002). 
The following measures were completed by patients post-intervention only: 
 Client Satisfaction Questionnaire (CSQ-8). The CSQ-8 (Larsen, Attkisson, Hargreaves, 
& Nguyen, 1979) was administered post-intervention only and used with author permission. The 
CSQ-8 is an eight item scale assessing general satisfaction with services provided, such as 
whether the participant’s needs were met, whether the participant would recommend the services 
to others, and overall satisfaction.  Response options differ item by item but each assesses 
satisfaction using a 4-item Likert anchored scale with item scores ranging from 1 to 4. Higher 
scores represent higher satisfaction. Examples include “How satisfied are you with the amount of 
help you have received?” (for which the response options are 1 = “Quite dissatisfied”, 2 = 
“Indifferent or mildly dissatisfied”, 3 = “Mostly satisfied”, 4 = “Very satisfied”, and “Have the 
services you received helped you to deal more effectively with your problems?” (for which the 
response options are 1 = “No, they seemed to make things worse”, 2 = “No, they didn't help”, 3 
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= “Yes, they helped somewhat”, 4 = “Yes, they helped a great deal”.  In order to better 
understand satisfaction as rated by this measure, we used a “school room” transformation method 
suggested by Attkisson and Greenfield (2009) that consists of summing the eight item scores and 
multiplying by 3.125 resulting in scores ranging from 25 to 100. Reported internal consistency of 
the CSQ-8 is strong (α = .92 - .93), construct validity appears adequate (i.e., clients who 
discontinue treatments were significantly less satisfied than those who do not, r = 0.37; 
satisfaction significantly correlated moderately with global improvement on a symptom checklist, 
SCL-90, r = 0.53) (Larsen et al., 1979; Attkisson & Zwick, 1982).  
Participant Satisfaction Questionnaire (PSQ). The PSQ was administered at post-
intervention only. The PSQ was created by the researchers conducting this study in order to 
evaluate satisfaction with specific aspects of this program, such as courtesy of program staff, 
convenience of scheduling, location and parking, tailoring of goals, helpfulness of the program, 
usability of materials, satisfaction with iPing automated phone calls, whether participants would 
recommend the program, whether participants would pay for the service, and overall satisfaction. 
Items are on a 5-point Likert scale with scores ranging from 1 (“strongly disagree”) to 5 
(“strongly agree”) and with a separate option of “no opinion”. Higher scores represent greater 
satisfaction.  
The following measures were completed by informants at baseline, post-intervention, and 
at one-month follow-up: 
Zarit Burden Inventory. The Zarit Burden Inventory (Zarit, Reever, & Bach-Peterson, 
1980) is a 29-item questionnaire used to assess caregiver burden in terms of personal and role 
strain. Items assess frequency of strain on a 5-point Likert scale from “Never” to “Nearly 
Always”. Higher scores represent higher burden. It has good internal consistency reliability (α 
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= .92) and is highly correlated with caregiver depression and behavior problems in the patient (p 
< 0.001) (Hérbert, Bravo, Préville, 2000).  
Statistical Analyses. Means, standard deviations, and frequencies were calculated to 
determine sample characteristics. Uniformity of treatment delivery was investigated by 
calculation of percentages. Feasibility was investigated by calculation of attrition rates. 
Acceptability was investigated by calculation means, standard deviations, and frequencies of 
satisfaction ratings provided by PD participants.  
As a primary outcome analysis, matched pairs t-tests were used to evaluate whether a 
significant difference was present between pre-intervention and post-intervention apathy scores 
(i.e., AES). To evaluate whether a significant difference was present between pre-intervention 
and post-intervention secondary outcome variables (i.e., patient depression, QoL, basic daily 
functioning, and carer burden/stress) from pre-test to post-test, further dependent paired t-test 
analyses were conducted. For exploratory purposes, another set of matched pairs t-tests were 
used to evaluate whether changes identified at post-test were maintained at one-month follow-up.  
Lastly, to investigate whether certain baseline variables (e.g., level of patient’s baseline 
cognitive function, degree of baseline functional impairment) were associated with response to 
treatment (i.e., defined as AES score at Time 2 minus AES score at Time 1), several correlations 
were examined. The results of these correlations provide some insight into what variables may 
guide inclusion/exclusion criteria in future uses of this intervention. 
Results 
 Patient demographics. Patient demographic information is summarized in Table 2. PD 
participants ranged in age from 44 to 86 years (mean = 66, SD = 10.7), were majority male (n = 
22, 81.5%) and Caucasian (n = 23; 85%), and ranged in disease duration from <1 to 23 years. All 
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patients had elevated apathy as determined by an inclusion cut-off score of 35 on the AES, 
representing a score greater than 1.0 SD above the mean of healthy elderly controls.  
 
Table 2 
Summary of sample demographics 
n = 27 n Range Mean (SD) 
Age 
 
27 44 - 86 66 (10.7) 
Disease duration 
(yrs) 
 
24 <1 - 23 10.1 (6.2) 
MMSE-II 
 
27 24 - 30 28.1 (1.5) 
Baseline Apathy 27 35 - 55 42.1 (41.0) 
 
 n % 
Gender 
     Male 
     Female 
 
 
22 
5 
 
81.5 % 
18.5 % 
Ethnicity 
     White 
     Hispanic 
 
23 
4 
 
85 % 
15 % 
 
 Treatment delivery. An adherence checklist was used as a guide during all sessions to 
ensure uniform treatment delivery (see Appendix). Sessions administered by newly trained 
undergraduate interventionists were audio-taped and tapes were reviewed by the P.I. and 
assessed for adherence to the protocol using the training checklist.  As reported above, adherence 
during the sessions administered by new trained interventionists ranged from 93% - 100%, with 
an average of 99% overall (96% for Planning Sessions and 100% for weekly phone sessions). No 
major deviations of the protocol occurred. Sessions administered by the P.I.were not recorded; 
therefore, adherence ratings of these sessions were unable to be evaluated.  
51 
 
 Feasibility. Treatment feasibility was assessed by investigating attrition rates and reasons 
for discontinuation of treatment. Of 34 participants who were initially enrolled and completed 
the initial Planning Session, two individuals attended the Planning Session but discontinued 
participation before completing Week 1, before beginning treatment. Reasons for their 
discontinuation included mistakenly thinking compensation would be provided for participating, 
feeling satisfied with their current level activity, and/or disinterest in the scheduling aspect of the 
study. Therefore, of the 32 who continued beyond the first meeting, 28 completed all six weeks 
of the study (12.5% attrition).  In addition, post-intervention data was not received from one of 
the subjects who completed the intervention.  Analyses reported include the 27 individuals who 
completed the 6-week program and for whom we received pre-intervention and post-intervention 
data. 
 Table 3 displays information of the four individuals who initiated treatment but 
discontinued treatment early.  
 
Table 3  
Summary of patients who discontinued treatment 
Subject Gender Age MMSE Disease 
Duration  
Baseline 
AES 
Duration of 
participation 
Reason for 
discontinuation 
1 
 
M 78 26 3.1 yrs 47 2 weeks - goals were not 
stimulating him  
- wife was pushing him 
to accomplish the 
planned goals 
2 
 
M 54 29 14.8 yrs 42 3 weeks - difficulty sticking to a 
schedule 
3 
 
F 75 28 2.1 yrs 42 4 weeks - medical 
complications 
prevented her from 
keeping up with goals 
- did not want to 
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disappoint PC by not 
fulfilling her obligation 
4 M 70 30 3.3 yrs 38 3 weeks - too busy with work 
and family visitors to 
keep track of goals 
- did not feel he could 
commit to 
accomplishing all goals  
 
 Acceptability. Acceptability of the study was measured by examining compliance and 
participant satisfaction ratings and related comments submitted by participants after completing 
Week 6. Compliance was measured by examining percentages of goal attainment. For most 
patients (and as is described in the PAL manual), two goals were planned for Week 1, three goals 
for Week 2, four goals for Week 3, and five goals for Weeks 4 to 6. Examples of goals selected 
by participants include walking a quarter mile three times weekly, practicing vocal exercises for 
10 minutes seven days per week, call son/daughter once per week, have lunch with a friend once 
weekly, work on specified household project once weekly. While most participants were 
engaging in five goals by Week 4, different goals required more or less engagements (e.g., some 
required initiation in the planned activity only once during the week while others required 
engagement seven times during the week). We evaluated compliance in three ways: (1) 
examining means, medians, modes, and quartiles of the raw number of goals completed in full 
(e.g., a participant who planned to exercise three times during the week only gets a point for 
completing the goal in full if s/he engaged in exercise three times; if s/he exercised only twice, 
the goal was not considered completed in full), (2) examining means, medians, modes, and 
quartiles of the raw number of activity engagements accomplished, and (3) examining the 
percentage of activity engagements accomplished relative to the number of activity engagements 
planned (i.e., number times participant engaged in an activity on the schedule ÷ number of total 
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engagements in activities planned for that week). This information is displayed in Tables 4, 5, 
and 6.  
Table 4 
Descriptives of raw number of goals completed in full, by week 
Week Mean (SD) Median Mode Quartiles Range 
    1 2 3  
1 1.5 (.7) 2 2 1 2 2 0-2 
2 2.3 (.8) 2 3 2 2 3 0-3 
3 3.1 (1.0) 3 4 2.5 3 4 0-4 
4 3.6 (1.0) 4 4 3 4 4 2-5 
5 3.2 (1.4) 3 2 2 3 4 1-5 
6 3.7 (.9) 4 4 3 4 4 1-5 
 
Table 5 
Descriptives of raw number of activity engagements accomplished, by week 
Week Mean (SD) Median Mode Quartiles Range 
    1 2 3  
1 5.5 (3.6) 4 2 2.25 4 8.5 1-13 
2 7.6 (4.6) 7 4 4 7 10 1-17 
3 10.2 (4.7) 9 6 6.5 9 12 4-24 
4 11.2 (6.2) 10 6 6.5 10 14.5 3-26 
5 11.0 (6.2) 9 9 6.25 9 15.75 2-25 
6 11.5 (5.9) 10 7 7 10 13.75 4-29 
 
Table 6 
Descriptives of percent activities engaged relative to number of activities planned, by week 
Week Mean (SD) Median Mode Quartiles Range 
    1 2 3  
1 93.8% (30.5) 100% 100% 82% 100% 100% 33.3-200% 
2 95.7% (29.7) 100% 100% 80% 100% 100% 28.6-175% 
3 96.7% (23.8) 100% 100% 83% 100% 111% 37.5-150% 
4 91.1% (31.2) 92.3% 100% 76% 92% 100% 17.7-162.3% 
5 87.6% (34.2) 88.7% multiple 63% 89% 115% 25-155.6% 
6 92.3% (23.9) 89.4% 100% 76% 89% 103% 36.4-135.7% 
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 As displayed, several participants exceeded the frequency of activity engagements at 
times by performing a planned activity more times during their week than they had planned, 
resulting in a percentage above 100 (e.g., a participant who planned to ride their bike 4 times but 
rode their bike 5 times instead would receive a percentage score of 125%). An examination of 
median scores demonstrate that at least 50% of participants were accomplishing at least 100% of 
planned activities during Weeks 1, 2, and 3, at least 92% during Week 4, and at least 89% during 
Weeks 5 and 6. An examination of quartiles demonstrate that 25% of participants were 
accomplishing at least 100% of planned activities during Weeks 1, 2, and 3, and that 25% of 
participants were exceeding their planned activity goals during Weeks 3, 5, and 6.  
 Patient participants of the program completed two satisfaction surveys upon completing 
their six-week program. Results of the CSQ-8, a measure of general satisfaction with the 
program, are presented in Table 7. Possible scores on this measure range from 25 to 100. In sum, 
obtained scores ranged from 71.9 to 100, with the most frequent score being 100, representing 
the highest level of satisfaction. 50% of scores (i.e., median) were at or above 87.5.   
 
Table 7 
Summary of CSQ Scores 
Mean (SD) 
 
86.9 (10.4) 
Median 
 
87.5 
Mode 
 
100.0 
Range 71.9 – 100.0 
Quartile 1 76.6 
Quartile 2 
(median) 
87.5 
Quartile 3 96.9 
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 Results of participant satisfaction as rated on the PSQ, a measure assessing satisfaction 
with specific aspects of this program, are presented in Tables 8 – 28. Overall, the majority of 
participants were satisfied with the overall program, indicated that the program helped them to 
deal more effectively with their problems, and would recommend the program to others. For 
instance, 88.5% of patients answered “strongly agree” and 3.8% answered “agree” to the 
statement “I was satisfied with the treatment provided by my program coach”. No patients 
reported disagreement with this statement.  
 While satisfaction with the program was overall very high, there were more mixed 
opinions of the iPing automated reminder call service and mixed opinions on whether 
participants would pay for the service themselves. To the item “I was satisfied with the 
automated iPing phone call reminders “, 60% of participants indicated “agree” or “strongly 
agree”, while 16% endorsed “disagree” or “strongly disagree”. 8% answered with “neither agree 
nor disagree” and 16% reported “no opinion”.  To the item “If I had to, I would pay for this type 
of services myself”, 25% of patients endorsed “agree” or “strongly agree”, while 30% of patients 
endorsed “disagree” or “strongly disagree”. 30% answered with “neither agree nor disagree” and 
15% reported “no opinion”. 88% of patients agreed or strongly agreed that the materials were 
easy to read and understand, while no patients expressed disagreeing with this.  
 Specific comments received from participants after completing the program are presented 
in Table 29.   
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Table 8 
My privacy was respected during the program. 
Response Frequency Percent 
Strongly agree 21 84.0 
Agree 2 8.0 
Neither agree or disagree 1 4.0 
Disagree 0 0.0 
Strongly disagree 0 0.0 
No opinion 1 4.0 
 
Table 9 
My program coach was courteous. 
Response Frequency Percent 
Strongly agree 25 96.2 
Agree 0 0.0 
Neither agree or disagree 0 0.0 
Disagree 0 0.0 
Strongly disagree 0 0.0 
No opinion 1 3.8 
 
Table 10 
All other staff members were courteous. 
Response Frequency Percent 
Strongly agree 10 40.0 
Agree 0 0.0 
Neither agree or disagree 0 0.0 
Disagree 0 0.0 
Strongly disagree 0 0.0 
No opinion 15 60.0 
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Table 11 
The program coach scheduled appointments at convenient times. 
Response Frequency Percent 
Strongly agree 21 80.8 
Agree 3 11.5 
Neither agree or disagree 1 3.8 
Disagree 0 0.0 
Strongly disagree 0 0.0 
No opinion 1 3.8 
 
Table 12 
I was satisfied with the treatment provided by my program coach. 
Response Frequency Percent 
Strongly agree 23 88.5 
Agree 1 3.8 
Neither agree or disagree 0 0.0 
Disagree 0 0.0 
Strongly disagree 0 0.0 
No opinion 2 7.7 
 
Table 13 
My first visit for the planning session was scheduled quickly. 
Response Frequency Percent 
Strongly agree 25 96.2 
Agree 0 0.0 
Neither agree or disagree 1 3.8 
Disagree 0 0.0 
Strongly disagree 0 0.0 
No opinion 0 0.0 
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Table 14 
It was easy to schedule phone calls after my initial planning session. 
Response Frequency Percent 
Strongly agree 18 69.2 
Agree 6 23.1 
Neither agree or disagree 0 0.0 
Disagree 1 3.8 
Strongly disagree 0 0.0 
No opinion 1 3.8 
 
Table 15 
I was seen promptly when I arrived for the planning session. 
Response Frequency Percent 
Strongly agree 22 84.6 
Agree 0 0.0 
Neither agree or disagree 0 0.0 
Disagree 0 0.0 
Strongly disagree 0 0.0 
No opinion 4 15.4 
 
Table 16 
The location of our first session was convenient for me. 
Response Frequency Percent 
Strongly agree 20 76.9 
Agree 4 15.4 
Neither agree or disagree 1 3.8 
Disagree 0 0.0 
Strongly disagree 0 0.0 
No opinion 1 3.8 
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Table 17 
I was satisfied with the services provided by my program coach. 
Response Frequency Percent 
Strongly agree 26 84.6 
Agree 1 3.8 
Neither agree or disagree 1 3.8 
Disagree 0 0.0 
Strongly disagree 0 0.0 
No opinion 2 7.7 
 
Table 18 
Parking was convenient for me. 
Response Frequency Percent 
Strongly agree 16 61.5 
Agree 0 0.0 
Neither agree or disagree 1 3.8 
Disagree 0 0.0 
Strongly disagree 0 0.0 
No opinion 9 34.6 
 
Table 19 
My program coach understood my goals and tailored them to me. 
Response Frequency Percent 
Strongly agree 21 80.8 
Agree 1 3.8 
Neither agree or disagree 0 0.0 
Disagree 0 0.0 
Strongly disagree 0 0.0 
No opinion 4 15.4 
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Table 20 
The instructions my program coach gave me were helpful. 
Response Frequency Percent 
Strongly agree 23 88.5 
Agree 1 3.8 
Neither agree or disagree 1 3.8 
Disagree 0 0.0 
Strongly disagree 0 0.0 
No opinion 1 3.8 
 
Table 21 
The materials provided were easy for me to read and understand. 
Response Frequency Percent 
Strongly agree 21 84.0 
Agree 1 4.0 
Neither agree or disagree 1 4.0 
Disagree 0 0.0 
Strongly disagree 0 0.0 
No opinion 2 8.0 
 
Table 22 
I was satisfied with the automated iPing phone call reminders. 
Response Frequency Percent 
Strongly agree 10 40.0 
Agree 5 20.0 
Neither agree or disagree 2 8.0 
Disagree 2 8.0 
Strongly disagree 2 8.0 
No opinion 4 16.0 
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Table 23 
I knew what was expected of me week to week. 
Response Frequency Percent 
Strongly agree 22 88.0 
Agree 1 4.0 
Neither agree or disagree 0 0.0 
Disagree 0 0.0 
Strongly disagree 0 0.0 
No opinion 2 8.0 
 
Table 24 
I was satisfied with the overall quality of my program. 
Response Frequency Percent 
Strongly agree 14 53.8 
Agree 5 19.2 
Neither agree or disagree 5 19.2 
Disagree 0 0.0 
Strongly disagree 1 3.8 
No opinion 1 3.8 
 
Table 25 
I would recommend this program to other Parkinson’s patients. 
Response Frequency Percent 
Strongly agree 20 76.9 
Agree 1 3.8 
Neither agree or disagree 4 15.4 
Disagree 0 0.0 
Strongly disagree 0 0.0 
No opinion 1 3.8 
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Table 26 
I would return to this facility if I wanted to participate in other research studies. 
Response Frequency Percent 
Strongly agree 13 65.0 
Agree 2 10.0 
Neither agree or disagree 0 0.0 
Disagree 0 0.0 
Strongly disagree 0 0.0 
No opinion 5 25.0 
 
Table 27 
If I had to, I would pay for this type of services myself. 
Response Frequency Percent 
Strongly agree 3 15.0 
Agree 2 10.0 
Neither agree or disagree 6 30.0 
Disagree 3 15.0 
Strongly disagree 3 15.0 
No opinion 3 15.0 
 
Table 28 
Overall, I was satisfied with my experience with the Parkinson’s Active Living program. 
Response Frequency Percent 
Strongly agree 15 75.0 
Agree 0 0.0 
Neither agree or disagree 3 15.0 
Disagree 0 0.0 
Strongly disagree 0 0.0 
No opinion 2 10.0 
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Table 29 
Post-Intervention Patient Comments 
• iPing was very helpful and easy to use. 
• Canceled iPing calls after the 4th week. The calls were starting to grate on me. 
• Feedback from Coach was helpful overall and gave me an incentive to be more productive. 
iPing was helpful even. Most important in terms of helpfulness, though, was the Coach calling 
me each week. 
• I found that having a list of tasks and calls to remind me a great help to me to get going and get 
things done. iPing really helped and it is was really gets me up and doing the activities. 
• I noticed that if the weekly calendar is not in front of me, I forget to do my activities. 
• I was not expecting any great changes in my apathy or enthusiasm but was wrong. I did lose the 
slow, apathetic fog that had been plaguing me. Feeling like my "old self" felt familiar and good. I 
didn't like iPing because it didn’t work properly- did not register “yes”, kept calling back, 
repeated questions. Frustrating! Setting goals and thinking about them during the week was 
helpful for me. The Program Coach's weekly calls were important because it showed I wasn't just 
forgotten about or treated like a number. And, pleasing the Program Coach helps! 
• iPing phone calls help. I'd like to use this myself from now on. Weekly calls also kept me on 
track. 
• My kids loved my increased contact with them! 
• My Coach was very nice and extremely easy to talk to! 
• Setting the goals and making a plan motivated me to get more done. It's what I used to do and I 
had gotten away from it. Having my Coach call each week also helped a lot because I wanted to 
please her by accomplishing what I'd set forth to do. iPing was not too important to me because I 
had it all in my own calendar. 
• This program was the nudge I needed to get moving. I wouldn't have accomplished as much 
without this program. iPing was helpful at the beginning but then after 3-4 weeks I set my own 
alarms. 
• This program changed my life! 
 
 Intervention Outcomes.  
 Diagnostics. The primary outcome variable was apathy severity. Secondary outcome 
variables included patients’ self-rated depression, quality of life, and daily functioning, and 
informants’ self-rated carer burden.  Examination of boxplots confirmed that data points of 
interest and change scores fell within acceptable limits (+/- 3 standard deviations from the mean) 
for analysis. Scores were normally distributed for most variables (Shapiro-Wilk test of normality, 
p < .05), with the exception of pre-intervention patient-rated apathy and post-intervention patient 
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depression. Patient rated apathy was normally distributed as assessed by Kolmogorov-Smirnov 
test of normality (p > .05), however, examination of normality using the Shapiro-Wilk test, a 
more rigorous test and often recommended with small samples sizes, showed deviation from 
normality (p <.05). Investigation into the distribution of pre-intervention apathy scores revealed 
that these variables were slightly positively skewed. Matched pairs/dependent t-tests are fairly 
robust to deviations from normality, however, to be conservative a square root transformation 
was applied to the data and analyses were run in two ways- using the original variable and using 
the transformed variable. No difference was observed in the results of the two approaches, 
therefore, all reported analyses were run on the original dataset.  Mauchly's Test of Sphericity 
when evaluating change across three time points indicated that the assumption of sphericity had 
not been violated (χ2(2) = 2.148, p = .342).  
 Primary outcome variable. Matched pairs t-tests, conducted to determine whether apathy 
severity scores as assessed by the self-report Apathy Evaluation Scale (AES), revealed that 
apathy was significantly different from pre-intervention (42.1 ± 6.0) to post-intervention (36.1 ± 
8.3) with a large effect (t(26) = -4.002, p < .0005; d = 0.77) with pre-intervention AES scores 
significantly higher than post-intervention AES scores . In terms of clinically significant change, 
mean apathy score pre-intervention was 2.2 SD above the mean of healthy elderly controls 
whereas post-intervention apathy levels were at 1.3 SD above the mean of healthy elderly 
controls. This demonstrates a drop of nearly 0.9 SD.  
 A look at change in pre-intervention to post-intervention apathy level at the individual 
participant level revealed that five participants (19%) showed a ≥ 2 SD decrease, nine 
participants (33%) showed a 1 to 2 SD decrease, and three participants (11%) showed a 0.5 to 1 
SD decrease in apathy from pre- to post-intervention. Ten participants (37%) went from having 
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elevated apathy (AES ≥ 35) to having apathy levels within a normal range (AES < 35). Apathy 
scores increased by 1-2 SD in two patients from pre- to post-intervention. 
 Secondary outcome variables. We were also interested in investigating whether the 
intervention may have had an impact on secondary variables, including patients’ self-rated 
depression, quality of life, and daily functioning, and informants’ self-rated carer burden. 
Patient’s self-rated depression significantly decreased from pre-intervention (13.61 ± 7.04) to 
post-intervention (10.78 ± 6.54), demonstrating a medium to large effect (t(22) = -3.380, p < .01, 
d = .70). In terms of clinical significance, the mean depression score pre-intervention (13.61) was 
qualitatively in the mildly depressed range and post-intervention (10.78) was qualitatively within 
normal limits as scores of 0-10 on the GDS represent depressive symptomatology in the normal 
range, scores of 11 or greater indicate the presence of at least mild depression (Yesavage et al., 
1983). A look at change in pre-intervention to post-intervention depression at the individual 
participant level revealed that three participants (11%) showed a ≥ 2 SD decrease, six 
participants (22%) showed a 1 to 2 SD decrease, and three participants (11%) showed a 0.5 to 1 
SD decrease in depression from pre- to post-intervention. Four participants (15%) went from 
having elevated depression (GDS ≥ 11) to having depression levels within a normal range (GDS 
< 11). Depression scores increased by 1 SD in one patients from pre- to post-intervention.  
 Patient’s self-rated quality of life significantly improved from pre-intervention (30.82 ± 
15.18) to post-intervention (25.51 ± 13.51), demonstrating a medium effect (t(23) = -2.458, p 
< .05, d = .50). No significant change was observed in patients’ self-reported basic daily 
functioning from pre-intervention (15.42 ± 6.48) to post-intervention (14.79 ± 5.91) (t(23) = -
1.17, p = .254; d = .24). No significant change was observed in informants’ self-reported carer 
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burden from pre-intervention (23.85 ± 17.92) to post-intervention (23.21 ± 17.82) (t(19) = -0.401, 
p = .693; d = .09). 
  One-month Follow-Up. Given that a significant change was present from pre-intervention 
to post-intervention in patient apathy, depression, and quality of life, matched pairs t-tests were 
conducted comparing post-intervention scores to one-month follow-up scores to examine 
whether these changes were maintained at follow-up. The decrease in apathy from pre-
intervention to post-intervention was maintained at one-month follow-up (36.9 ± 7.0) as reflected 
by a significant difference between pre-intervention (42.2 ± 6.0) and one-month follow-up (37.0 
± 7.4) apathy scores (t(19) = -4.264, p < .0005; d = .95) and no significant change from post-
treatment (35.1 ± 7.5) to one-month follow-up (37.0 ± 7.4) (t(19) = 1.213, p = 0.24; d = .27).  
 The decrease in depression from pre-intervention to post-intervention was also 
maintained at one-month follow-up as reflected by a significant difference between pre-
intervention (13.61 ± 7.04) and one-month follow-up (10.2 ± 6.5) depression scores (t(17) = -
4.002, p < .005; d = .94) and no significant change from post-treatment (10.78 ± 6.54) to one-
month follow-up (10.2 ± 6.5) (t(15) = -.265, p = 0.80; d = .07).  
 The improvement in quality of life from pre-intervention to post-intervention was not 
maintained at one-month follow-up. There was no significant difference between pre-
intervention (30.82 ± 15.18) and one-month follow-up (27.0 ± 14.8) in quality of life scores 
(t(17) = -0.975, p = .343; d = .23), nor was there a significant change from post-treatment (25.51 
± 13.51) to one-month follow-up (27.0 ± 14.8) (t(18) = 0.681, p = 0.51; d = .16). 
 Associations with Change. To investigate whether certain baseline variables were 
associated with response to treatment (i.e., defined as AES score at Time 2 minus AES score at 
Time 1), several correlations were examined (see Table 30).  
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Table 30 
Correlations between baseline variables and response to treatment 
 MMSE-
II 
Disease 
duration 
GDS AES LARS: 
Novelty 
Seeking 
LARS: 
Self-
Awareness 
COWA
a
 Animal  
Naming
a
 
Response 
to 
treatment 
-.165
ns
 .048
ns
 -.160
ns 
-.287
 
ns
 
.415
t 
(n=20) 
.410
t 
(n=20) 
-.483
* 
(n=17)
 
.085
ns
 
 
MMSE-II: Mini Mental Status Examination-II; GDS: Geriatric Depression Scale; AES: Apathy Evaluation Scale-Self; LARS: Lille Apathy Rating 
Scale; COWA: California Oral Word Association test 
a 
Verbal fluency scores are reported for participants who speak English as a first language  
*
 p<0.05 
**
p<0.01 
t
 trend, p=.07  
ns
 not significant, p>0.05 
 
Investigation of correlation coefficients revealed no significant correlation between response to 
treatment and baseline global cognitive function (MMSE-II total score), category fluency, 
duration of disease, or baseline apathy or depression scores. However, response to treatment was 
significantly and negatively associated with baseline phonemic fluency, a measure related to 
frontal executive functioning (COWA scaled score corrected for age and education), reflecting 
that higher executive functioning was related to greater change in apathy from pre-test to post-
test. A small to moderate positive trend was present in the correlation between response to 
treatment and apathy related to novelty seeking (LARS Novelty Seeking subscale) and self-
awareness (LARS Self-Awareness subscale) in that patients who endorsed greater motivation 
behavior toward novelty seeking and those who endorsed greater motivation behavior toward 
self-evaluation/self-awareness showed a greater decrease in apathy from pre-intervention to post-
intervention.   
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Discussion 
 
The purpose of the present study was to develop and gather pilot data on the 
acceptability, feasibility, and effectiveness of a primarily telephone-based, 6-week activity 
scheduling and monitoring intervention that incorporates an external cueing component to target 
disease-related self-generational deficits, on reducing levels of apathy in non-demented, highly 
apathetic PD patients. Specific aims of this study included (1) developing the PAL program 
protocol and materials, including a guide, or manual, for interventionists to use to administer the 
PAL program and a participant workbook for patient participants; (2) determining feasibility or 
ease of training new interventionists as determined by rates of protocol adherence during 
protocol administration following training; and (3) obtaining pilot data on the feasibility of 
implementing the treatment protocol and retaining participants through the duration of the 
program in a population of non-demented PD patients, on the acceptability or perceived 
satisfaction of the program, and to determine a within-subject effect on primary (i.e., patient 
apathy) and secondary (i.e., patient depression, quality of life, daily functioning, and spousal 
burden) variables by evaluating effect sizes. 
We hypothesized that a behavioral intervention aimed at increasing activity 
identification, goal-setting, and activity engagement that incorporated an external cueing 
structure would benefit the apathetic PD patient and their spouses by improving patient apathy, 
depression, quality of life, daily functioning, and spousal burden. The Brief Behavioral 
Activation Treatment for Depression (BATD; Lejuez et al., 2001) served as the foundation from 
which the PAL program was developed in that its structure was replicated and several forms 
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from the BATD manual were either adapted for easier use with PD patients or used without 
adaptation. The PAL program was delivered primarily as a telephone-based intervention as it 
required one in-person Planning Session with the remaining six sessions occurring by telephone. 
It was designed with important factors for behavior change in older adults in mind, including 
attention to the provision of social support, consideration of self-efficacy, program tailoring, 
goal-setting, weekly performance feedback, and positive reinforcement (Cress et al., 2005), as 
well as applying our knowledge of the benefit of external structure and cueing for PD patients 
specifically. The program was designed as an individually tailored program in which activities 
reflecting the participants’ preferences and capabilities were selected by participants after 
brainstorming ideas with their Program Coach, was flexible week to week to prevent threats to 
self-efficacy, and incorporated goal-setting with weekly guidance and reinforcement through 
telephone check-ins with their Program Coach.  Spouses were not involved in an effort to 
facilitate self-management and patient independence; patients were encouraged to self-identify 
goals during the Planning Session and spouses were not required to be actively involved in the 
study outside of optionally completing questionnaires at three time points.   
Feasibility of Interventionist Training 
 Following the development of the PAL protocol, administration manual, and participant 
workbook, four new undergraduate or post-baccalaureate student interventionists were trained to 
determine ease of training and fidelity of treatment implementation by new interventionists 
following training sessions. Prior studies have shown success in using “paraprofessionals” to 
deliver psychosocial interventions to promote self-management of behavior (Sacco, Malone, 
Morrison, Friedman, & Wells, 2009; Sacco, Morrison, & Malone, 2004; Christensen & 
Jacobson, 1994). Training included three training sessions, during which trainees reviewed the 
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PAL treatment manual, forms, and assessment measures; learned to administer baseline 
evaluations; received readings on apathy in PD, goal-setting theory and the use of 
implementation intentions (i.e., how to design goals that increase the likelihood of goal 
attainment), and research on the benefits of external cueing in PD; and engaged in role plays. 
Interventionists were encouraged to use the training checklist and manual during sessions to 
ensure uniformity of treatment. Ease of training was confirmed by rating four newly trained 
paraprofessional interventionists, or Program Coaches, on adherence to the protocol during 
administration. Overall, newly trained interventionists were able to display 97% adherence (94% 
for Planning Sessions, 100% for Phone Sessions) during a mock session role play with the P.I. at 
the end of training and 99% adherence (96% for Planning Sessions, 100% for Phone Sessions) 
when working with patient participants.  
 While the number of newly trained interventionists is small, this data provides promise 
for training paraprofessional interventionists with ease through the provision of psychoeducation 
and role plays and for competency in terms of uniformity of administration to be able to be 
demonstrated rather quickly, within three separate training sessions totaling approximately six 
hours. In addition, newly trained interventionists had not been previously trained in 
psychotherapy; rather, they were undergraduate research assistants with an interest in pursuing 
graduate school in clinical psychology. Since the P.I. of the present study, a doctoral candidate 
with therapy experience, served as the Program Coach for the majority of participants in this 
exploratory study, we cannot speak to whether or not acceptability of this program by this patient 
population would have been different had the newly trained interventionists served as Program 
Coaches for all participants in this study.      
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Feasibility of Enrollment 
 It was expected that recruitment would be slow due to several anticipated barriers, 
including targeting a population of individuals who are not only experiencing difficulties in 
motor functioning but also specific difficulties with motivation and initiative, requiring a 
minimum of a six week time commitment by participants, expecting active involvement in the 
intervention over six weeks by requiring participants to document accomplishment of planned 
activities and to attend weekly phone sessions, and the lack of compensation for participating. 
However, recruitment proved to be even slower than expected. Efforts were made early on to 
minimize enrollment difficulty by choosing to design the protocol to be primarily delivered as a 
telephone intervention with exception of the first session occurring in-person. Prior studies have 
shown telephone delivery of behavioral interventions to be successful in offering cost-effective 
mental health services (e.g., McBride & Rimer, 1999; Sacco et al., 2004, 2008; Eakin, Lawler, 
Vandelanotte, & Owen, 2007). Efforts were also made to minimize the number of exclusion 
criteria in order to cast a wider net during recruitment, including reducing the typical AES cut-
off from 38 to 35 points. Additionally, recruitment began in the Tampa Bay region but was 
extended to include the Orlando, Gainesville, The Villages, and surrounding areas.  
A large number of individuals who expressed interest in participating failed to qualify 
due to an AES score falling below the cut-off score of 35. Interestingly, several individuals who 
were referred to our study from UF based on having a “high apathy” score on the Apathy Scale 
(AS; Starkstein et al, 1992a), another measure commonly used to assess apathy in PD patients, 
during their UF clinic or research visit did not qualify for our study when they completed our 
AES as a screening measure. Other institutions with a focus in PD research, such as the 
University of Florida, have used the AS to assess apathy symptoms in their clinics and in their 
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PD research. The AS, which was abridged from the AES (which we used), consists of 14 items 
on a four point Likert scale (0-3; “Not at all” to “A lot”), has been recommended for use with PD 
patients (Leentjens et al., 2008), and also has good psychometric support (Starkstein et al., 
1992a; Ferencz et al., 2010). Sensitivity and specificity was determined for the AS by comparing 
scores to whether a neurologist classified patients as apathetic or nonapathetic (66% sensitivity, 
100% specificity; Starkstein et al., 1992a), however, specificity and sensitivity of the AES has 
not been determined. Since neither measure has been evaluated for sensitivity or specificity 
against a “gold standard”, it is difficult to predict how use of the AS versus the AES would affect 
recruitment. A task force of apathy researchers was recently created to identify criteria for 
diagnosing apathy, which has since been published (Robert et al., 2009) and could be used at this 
point to evaluate the sensitivity and specificity of both the AES and AS. 
 Ultimately, the Michael J. Fox Trial Finder, a rather new service that connects PD 
researchers to PD patients, proved to be a very efficient method for recruitment. In order to 
register a study onto the site, researchers must submit proof of approval from a university’s 
Institutional Review Board (IRB), which staff of the Trial Finder review. Once approved, 
researchers can browse through individuals whose basic demographic and disease criteria match 
study inclusion criteria and may contact participants through a two-way anonymous messaging 
to inform them of the study. Unfortunately, the service was officially launched in April of 2012 
and the researchers of this study were not aware of this service until several months into the 
study. Currently, just under 20,000 individuals across the United States have registered as PD 
patients or PD caregivers who are interested in participating in research. The site was recently 
launched in the UK, Ireland, and Canada as well. This resource will do wonders to increase the 
ease of conducting future research in PD.  
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Feasibility of Retention 
 Treatment feasibility was assessed by investigating retention through attrition rates and 
participants’ reported reasons for discontinuing treatment. Two individuals who attended the 
Planning Session discontinued participation before engaging in Week 1 activities (i.e., before 
initiating treatment) due to mistakenly thinking compensation would be provided for 
participating, feeling satisfied with their current level activity, and/or disinterest in the scheduled 
structure of the study. 82% of those who enrolled completed the program and 87.5% of 
participants who began treatment following the Planning Session persisted through all six weeks 
of the program. We are unaware of data that reports rates of adherence to similar behavioral 
interventions with Parkinson’s patients, however, one study reported adherence rates of 79% for 
PD patients participating in a home-based exercise program. Those who were older, reported 
higher disease severity, and who endorsed extreme depression or anxiety reported even lower 
adherence to exercise (47%) (Pickering, Fitton, Ballinger, Fazakarley & Ashburn, 2013). 
Ongoing social support, provided by the Program Coach during the PAL program, also likely 
contributed to adherence. Ravenek and Schneider (2009) demonstrated that social support and 
perceived control both played an important role in PD patients’ willingness to adhere to 
participation in an exercise program. More generally, therapeutic alliance research has shown 
that a positive therapeutic relationship has served as a contributing mechanism of change in 
outcome research for various psychotherapies (Lambert & Barley, 2002). 
 Review of participants’ reported reasons for discontinuing treatment reveals that barriers 
to continued participation in this program may include concern over not being able to achieve 
100% of activity goals and disappointing their Program Coach, disinterest in having to follow a 
schedule of planned activities, feeling satisfied with level of baseline activity, feeling as if the 
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selected goals are not stimulating enough, interference of unexpected medical complications, and 
the negative involvement of a spouse or caregiver.  
 While some of these barriers, such as new onset of medical complications, cannot be 
prevented, recognition of others may be useful during recruitment and during interactions with 
participants early on and over the course of their participation. For instance, ensuring that 
individuals are aware that they will be expected to follow a schedule of activities and that 
participants join if and only if they recognize a problem with their level of activity may increase 
retention. Further, Program Coaches should emphasize that participants do their best rather than 
attempting to achieve 100% of the plan and should be highly attentive to goal difficulty and 
feasibility when helping participants select goals. As past research has demonstrated in the field 
of workplace motivation, effective goals must also be somewhat challenging but, importantly, 
attainable (Bandura, 1991; Bandura and Cervone, 1983; Locke and Latham, 1991, 2002). Goals 
that are too easy fail to motivate the individual and goals that are impractical in attainment are 
discouraging. The Program Coach is essential in ensuring that participants feel a sense of 
competence by gauging aspects of goal challenge week to week, foreseeing problems with this 
before they arise, and adjusting the plan before a participant becomes too discouraged or too 
bored.  
Acceptability 
 In order to better understand how the intervention program was accepted by participants, 
we investigated compliance and satisfaction ratings. For most patients, two goals were planned 
for Week 1, three goals for Week 2, four goals for Week 3, and five goals for Weeks 4 to 6, 
although this standard procedure was adjusted slightly to tailor to individual participant needs. 
To reiterate, each goal specified an activity to target per week and each goal varied in its 
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frequency of planned engagement and in its duration. For instance, a participant may have 
selected during the first week to engage in Tai Chi exercise only once during the week but to 
engage in that same Tai Chi exercise daily (i.e., seven times) during Week 5. At the end of the 
week, the goal was only deemed completed in full if and only if the participant engaged in that 
planned activity the number of times planned. Therefore, we evaluated goal compliance by 
examining descriptives of the number of goals participants were able to complete in full each 
week, descriptives of the number of individual activity engagements accomplished each week, 
and percentages of activity engagements accomplished relative to the number of activity 
engagements planned.  
 A summary of statistics related to goal achievement were presented in Tables 4 – 6. 
Examination of this data may help in the future implementation of the program by helping 
Program Coaches to set expectations for clients and to recognize times at which goal attainment 
commonly becomes difficult. A look at quartile data revealed that the majority of patients had no 
difficulty meeting all planned goals in full during Weeks 1 (i.e., two goals), 2 (i.e., three goals), 
and 3 (i.e., four goals). They achieved greatest compliance during the first three weeks, engaging 
in over 94% of planned activities on average, with a median of 100% of planned activities 
achieved. Compliance dropped slightly after this point, but participants were still engaging in 
over 88% of planned activities on average during the final three weeks, with medians of 89% - 
92%.  
 The majority of participants were unable to accomplish more than four goals in full 
despite the fact that five goals were planned for participants in Weeks 4 to 6. In fact, less than 
25% were able to accomplish all five goals during Weeks 4 and 5 and less than 15% of 
participants were able to accomplish all five goals during Week 6. This suggests that setting 
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more than four goals may increase challenge. While this raises questions as to whether setting 
four goals is too arduous, that determination must be made client to client by the Program 
Coach’s estimate, however, we expect that setting more than four goals may generally help to 
increase challenge, which is an essential element in increasing motivation according to goal-
setting theory (Locke & Latham, 1990). At the very least, and considering that one of the 
common reasons given for early discontinuation of treatment in this study was participants’ 
concern that they could not achieve the goals set, we believe it is important for Program Coaches 
to warn participants that it may become more challenging after Week 3 to achieve all goals set 
but to encourage participants to do their best even if unable to achieve all goals planned.   
 In terms of participants’ satisfaction with the program, the majority of participants were 
satisfied with the program overall, indicated that the program materials were easy to read and 
understand, that it helped them to deal more effectively with their problems, and that they would 
recommend the program to others. One participant reported that the program helped her to lose 
the “slow, apathetic fog that had been plaguing [her]” and that “feeling like [her] old self felt 
familiar and good.” One participants specifically reported that the program “changed [his] life”. 
Some participants requested blank copies of the weekly calendars to use independently after 
participation in the study was complete. 
 While reports of satisfaction with the program were generally very high, there were 
mixed opinions on two things. Firstly, participants gave mixed reviews of the iPing automated 
reminder call service. 60% of participants endorsed satisfaction with the iPing reminder calls 
while 16% endorsed dissatisfaction with this service. Additionally, use of the iPing system was 
also one of the most demanding aspects for the Program Coach to manage as setting up the calls 
was somewhat time consuming and required weekly attention, particularly if goals were adjusted 
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during the program. The system was not only unreliable at times for participants (i.e., sending 
multiple reminders of the same goal, not sending calls when scheduled), but it was unreliable at 
times for Program Coaches during initial set-up as well in that the service was out of order on 
two occasions, lasting up to three weeks at one point in time. As this study did not investigate 
mechanisms of change, the importance of this component of the intervention is unknown. 
 Secondly, participants were mixed on whether they would pay for the PAL service 
themselves. 25% of patients indicated that they would pay for the services provided in the PAL 
program themselves while 30% of patients indicated that they would not. A survey of PD 
patients inquiring how much money they would pay for this service would be useful, particularly 
for follow-up studies and if this program is to be distributed or made available for consumers in 
the future.  
Outcomes 
 Primary outcome analyses revealed a large effect of the treatment on apathy severity 
from pre- to post-intervention and the change in scores was clinically significant as represented 
by a nearly 0.9 standard deviation drop in apathy score. 19% showed a ≥ 2 SD decrease and 33% 
of participants showed a 1 to 2 SD decrease in apathy score from pre- to post-intervention. 37% 
of participants went from having significantly elevated apathy (AES ≥ 35) to having apathy 
levels within a normal range (AES < 35), demonstrating that several participants who were 
experiencing significantly and clinically elevated apathy were no longer experiencing unusual 
elevations post-intervention. This reduction in apathy was maintained at one-month follow-up. 
Given that this was not a controlled study, we cannot determine the mechanism of change or say 
with confidence that the changes observed were due to the intervention itself. We also cannot 
determine how these changes were maintained as we did not gather data on whether participants 
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continued to practice skills or whether they utilized materials (e.g., weekly checklists, weekly 
calendars, iPing). These concerns are discussed in detail below under “Limitations”. 
 Secondary outcome analyses revealed a medium to large effect of treatment on patient 
depression and a medium effect on patient quality of life. A look at changes in individual scores 
shows that the changes in depression were not as dramatic as those in apathy in that only 15% of 
participants showed a change from having elevated depression (GDS ≥ 11) to having depression 
levels within a normal range (GDS < 11). However, 33% of participants showed a greater than 1 
SD drop in depression score, which is generally considered to reflect clinically significant 
change. Change at one-month follow-up was also maintained for depression but not for quality 
of life ratings. The effect of treatment on patients’ self-reported basic daily functioning, as 
measured by independence in basic activities of daily living, was small and present (d = .24) 
although non-signficant. The effect of treatment on carer burden was non-significant (d = .09).  
 While we are unaware of any studies that have evaluated the impact of behavioral 
activation alone on depression or apathy in PD, our findings that increasing activity engagement 
was related to decreases in apathy and depression over time is not too surprising given the 
success of recent trials evaluating the effect of modified cognitive behavioral treatment (CBT) on 
depression in PD using in-person and telephone delivery. Dobkin and colleagues (2007) showed 
that modified CBT improved depression in depressed PD patients in a single-arm, uncontrolled 
trial. A follow-up investigation using a randomized controlled trial (RCT) design further 
supported the effectiveness of CBT on depression in depressed PD patients (Dobkin et al., 
2011a). This group also recently found that telephone delivery of CBT on depression in PD 
(Dobkin et al., 2011b) reduced depression in PD patients. They will likely follow-up this study 
with an RCT.  
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 Given the high prevalence of apathy and depression in PD, these results show promise 
that improving motivation and mood by means of a behavioral approach, rather than a 
pharmacological approach, is possible in PD. Notably, a number of participants in this study 
were on medications that have shown to improve apathy and mood; therefore, it is not clear 
whether this behavioral intervention would be effective had patients been required to discontinue 
pharmacologic treatments.  
Predictors of Response to Treatment  
 To investigate whether certain baseline variables were associated with response to 
treatment, several correlations were examined. Investigations revealed that individuals with 
better verbal phonemic fluency were more likely to show a greater reduction in apathy from pre- 
to post-intervention. This information is interesting as it suggests that the utility of the PAL 
program may depend, in part, on the integrity frontal executive functioning. Verbal phonemic 
fluency is dependent upon left inferior frontal cortex and subcortical structures generally 
(Costafreda et al., 2006; Hirshorn & Thompson-Hill, 2006; Schlosser et al., 1998) and with 
reduced caudate grey matter volume in PD (Ellfolk et al., 2013) and is related to executive 
functioning, slow speed of processing, and apathy.  Interestingly, a recent study similarly showed 
that higher executive functioning, as assessed using a task of frontal cognitive flexibility and set-
shifting (Trail Making Test), was a significant predictor of response to CBT for depression in PD 
patients (Dobkin et al., 2012). We only assessed one aspect of executive functioning, however, it 
would be interesting to investigate the relationship of treatment response with other aspects of 
executive functioning. The term executive functioning is a broad label for cognitive functions 
associated with frontal-subcortical circuits, including one’s ability to be cognitively flexible, 
generate new concepts, elaborate cognitive and behavioral responses to environmental situations, 
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adapt to novel situations, set-shift, problem solve, plan and organize, inhibit oneself, process 
information quickly, and to retrieve information freely from memory without cues. Involvement 
in the program required several aspects of executive functioning, including brainstorming of 
goals, willingness to engage in new activities, ability to make changes to one’s day-to-day 
activity engagement, ability to flexibly adjust goals week to week when necessary, and 
willingness to push beyond one’s comfort level. Some supports were provided, of course, to 
account for the executive difficulties common in PD, such as the provision of a Coach as a guide 
during brainstorming and throughout the program, a structured calendar of activities, and iPing 
reminder calls. 
  Response to treatment in our study was not related to global cognitive functioning. It is 
possible that this finding may have differed had we evaluated global cognitive functioning using 
a measure that better assess executive functions, such as the Montreal Cognitive Assessment 
(MoCA; Nasreddine et al., 2005) or the Parkinson’s Disease – Cognitive Rating Scale (PD-CRS; 
Pagonabarrage et al., 2008). The measure of global cognitive functioning that we used, the 
standard score of the MMSE-II, is not heavily reliant on executive skills.  
 In addition, a positive trend suggests individuals who describe themselves as having 
greater motivation behavior toward novelty seeking and those who describe themselves as 
having greater motivation behavior toward self-evaluation/self-awareness (as measured by the 
LARS)  may be more likely to find a greater benefit from this intervention. In other words, 
individuals who show greater interest in seeking new experiences are more likely to benefit from 
this program as are individuals who are comfortable with and able to evaluate whether they are 
doing well or poorly and to make adjustments to their behavior based on their self-evaluation. 
This raises questions such as what other personality variables (for instance, openness to 
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experience, conscientiousness, and extraversion), may also be associated with response to 
treatment. Some of the individuals that discontinued our program reported that the reason for 
their early discontinuation had to do with disliking the scheduling aspect of the program. Perhaps 
individuals with greater desire for flexibility, such as those who might score as those who might 
score as a “judging” (versus “perception”) lifestyle type on the Myers-Briggs Type Indicator 
(MBTI; Myers, Briggs, McCaulley, Quenk, & Hammer, 1998), would be more likely to refuse to 
participate, discontinue early, be noncompliant, or benefit from the program overall.   
Study Limitations 
 While the present study shows promise for the potential beneficial impact of the PAL 
program on improving apathy, depression, and quality of life in patients with PD, the findings 
should be interpreted with caution due to several limitations to the design and methodology that 
compromise the internal validity of our results and challenge the implications of our findings. 
Internal validity refers to the extent to which a cause and effect relationship can be determined 
within a study. A study that is considered to have good internal validity is able to demonstrate 
that the proposed “cause” precedes the “effect”, that the proposed “cause” and “effect” are 
correlated, and, importantly, that alternative explanations (i.e., possible third variable “causes”) 
are controlled for and ruled out (Shadish, Cook, and Campbell, 2002). The lack of a randomized 
time and attention control group in this study prevents us from being able to draw firm 
conclusions about the reasons underlying observed change in apathy, depression, and quality of 
life. We are unable to determine whether the change occurred as a result of the intervention itself 
or as a result of alternative threats, such as attrition bias, experimenter bias, or participant effects. 
 Attrition bias is a type of selection bias cause by attrition. Given that our analyses were 
run on only those subjects who participated throughout the full six weeks of the study, it is 
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possible that participants who were feeling a benefit of the program were more likely to stay 
enrolled in the study for the duration while those who did not feel an improvement in their 
motivation, mood, or quality of life may have been the ones to drop out, therefore increasing the 
perceived effect of treatment.  
Experimenter bias refers to the potential for researchers to inadvertently influence the 
behavior of the participants in a way that facilitates the experimenter’s desired outcome. Since 
the P.I. was the primary interventionist in the study and was keenly aware of the hypotheses 
being tested, was involved in all aspects of the study (recruitment, protocol administration, and 
analysis), and all parties were aware of the treatment received by each participant, the possibility 
of experimenter bias is a limitation. Importantly, efforts were made to minimize this where 
possible, including use of specific inclusion criteria to minimize experimenter bias in selection of 
participants, standardization of administration procedures through the use of an administration 
manual and adherence checklist, the use of research assistants for the majority of data entry, and 
double-checking of all data by a second rater to verify accurate data entry.  
 In addition, participant effects or demand characteristics may threaten validity in that 
some participants explicitly stated a desire to satisfy their Program Coach. The fact that we found 
significant changes on select measures and not on all measures suggests this may not have been 
the case. Efforts were made to minimize this by informing participants of the importance of data 
accuracy over pleasing their coach and encouraging all participants during all phone sessions to 
report honestly. Given that the accountability to an outside person’s evaluation likely serves as 
an important motivator for participants to improve their activity level, inclusion of a control 
group in a single-blind study would help control for the influence of participant effects.  
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 Given that the current study was conducted on a selective population, specifically, 
individuals diagnosed with PD who were not suspected of severe cognitive impairment based on 
a score ≥ 24 on the MMSE-II, we cannot speak to the utility of the PAL program with other 
populations, such as its generalizability to PD patients with severe cognitive impairment, other 
patients with neurodegenerative disease (e.g., Huntington’s disease, Progressive Supranuclear 
Palsy, Alzheimer’s disease), or to healthy elderly individuals experiencing apathy. Within our 
sample, exclusion criteria were minimized in order to increase generalizability within a non-
demented PD population specifically. In addition, minority groups were underrepresented in this 
sample and the sample was primarily male, making generalizability to underrepresented groups 
unclear. Further, individuals who volunteered in the study may be qualitatively different than 
those who did not. We suspect that those who chose to participate have at least some interest and 
motivation toward self-improvement, toward satisfying a spouse who may have urged them to 
participate, or to contribute to research in PD.    
 While the sample size of our study is equivalent to and even larger than similar 
intervention studies that have been conducted in PD (e.g., Dobkin et al., 2007), power analysis 
suggest that our sample would have been too small to detect anything less than a medium effect 
of treatment at post-intervention and a large effect of treatment at one-month follow-up due to 
attrition of responders at the one-month follow-up time point. A larger sample size would not 
allow detection of smaller effects on dependent variables of interest, but would also allow us to 
do further exploratory analyses. For instance, it would be interesting to investigate whether 
differences existed in response to treatment between individuals with apathy but no depression 
and individuals with apathy plus depression, males versus females, mildly elevated baseline 
apathy (1 – 1.5 SD above the mean) versus extremely elevated apathy (>2 SD above the mean), 
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and whether the type of activity (e.g., physical exercise, social involvement, cognitive/learning 
activity) or number of activities selected by participants may have determined their response to 
treatment or satisfaction with the program. 
Future Research 
 There are several ways in which future research can help to clarify the benefit of the 
present intervention on this and other populations of interest. Firstly, pursuit of a single-blind 
randomized controlled trial (RCT), which includes randomized assignment to a PAL treatment 
versus an attention control group and possibly an additional usual care or psychoeducation only 
control condition, would be ideal as it would provide control over several factors that pose 
threats to the internal validity of the present study. An RCT would afford investigation of 
whether improvements in patient apathy, depression, and quality of life that were observed in 
this study are explained by components of the PAL intervention itself or to alternative 
explanations discussed.  
 A larger sample size would be helpful in allowing examination of whether other patient 
or caregiver variables are impacted by this intervention, such as frontal executive functioning or 
other cognitive functions in patient participants, mood in spouses or caregiver, and relationship 
satisfaction in both patients and spouses. A larger sample size would also provide increased 
power to examine differences in sample characteristics and other correlates that may moderate or 
mediate response to change, such as baseline apathy and depression levels, current executive 
functioning abilities of all types (e.g., fluency, set-shifting, problem solving, planning and 
organization, decision making), disease variables (e.g., disease duration, stage of disease, 
comorbidities, medication status), motivation to change, and differences in personality 
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characteristics (e.g., rigidity, flexibility, desire for structure, consciensciousness, agreeableness, 
openness to experience).  
 Because the present program includes multiple components (e.g., brainstorming life areas 
needing improvement, the act of goal-setting, use of strategies during goal setting such as the 
SMART acronym and implementation intentions, the use of automated iPing calls, weekly 
contact with a Program Coach who provided praise and encouragement, identification and 
attainment of a reward when all goals were met at the end of a week) and activities ranged in 
difficulty, type (e.g., physical activity vs. increasing learning vs. increasing social contact vs. 
increasing engagement in household projects), and frequency across participants, we were unable 
to determine which of these many factors, individually or in combination, were responsible for 
observed change in dependent variables, if any. Future investigations of mechanisms of change 
can help distinguish between the influence and necessity of these different factors, which can 
contribute to the inclusion of factors that are key to effecting change and to the exclusion of 
factors deemed less essential.  
 Further, we do not know whether level of training within the field of psychology for 
Program Coaches may have also influenced the acceptability and/or effect of the intervention, 
although paraprofessionals, including undergraduate student interventionists, have been used to 
implement self-management interventions with good success (Sacco et al., 2009; Sacco et al., 
2004; Christensen & Jacobson, 1994). Given that training of PAL Program Coaches proved to be 
rather quick and adherence by newly trained interventionists was strong, we suspect that training 
of paraprofessionals would be successful. However, we also expect that the rapport built between 
the patient participant and the Program Coach is also important. The therapeutic relationship or 
presence of therapist support has often been reported as an important element of both program 
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participation in PD patients (Pickering et al., 2013) as well as response to intervention in 
psychotherapy in various populations (Lambert & Barley, 2002), and it is likely that the 
therapeutic relationship is also important for response to treatment in this program as well.  
 Interestingly, we received about five requests to participate from individuals who lived 
out of state or overseas. We did not include participants who were unable to attend one in-person 
session, however, we are interested in whether this program could be administered via Skype if 
materials are provided to participants to review during an online face-to-face session. Some 
studies have shown successful treatment outcomes with PD patients using treatments delivered 
online. For instance, Constantinescu and colleagues (2011) showed successful delivery and 
receipt of vocal training for the treatment of hypokinetic dysarthria in PD patients using online 
delivery.  Online delivery of cognitive-behavioral therapy through emailing has been effective 
for individuals (not with PD) diagnosed with depression, generalized anxiety disorder, and social 
anxiety disorder (e.g., Andersson, 2009; Andersson et al., 2012).  
 Given that some patients expressed dissatisfaction with the iPing automated reminder 
system, we suggest that follow-up studies consider using alternatives to this system that are more 
reliable and easier for the interventionists to manage. Identification and use of a text messaging 
service may be most ideal as many individuals in our study owned and regularly used a cell 
phone. We also recommend studies to include follow-ups beyond one month in order to evaluate 
whether observed changes persist longer term. Finally, it would also be useful to gather survey 
data on how much individuals would be willing to pay for this type of service. This kind of data 
might provide more compelling support for the pursuit of future research to grant funding 
agencies.  
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 Investigations into whether other populations may benefit from this study is also 
warranted. Apathy is also common in a number of other neurodegenerative diseases, including 
Alzheimer’s disease, Huntington’s disease, and Progressive Supranuclear Palsy. Due to the need 
to be able to understand how to use the weekly calendar and checklist, we expect that individuals 
with dementia would have great difficulty following this program on their own. However, it may 
be the case that caregivers of patients could be trained to implement the program with their loved 
one. In this case, caregivers would provide prompting to their loved one when it is time to 
engage in a scheduled activity. Whether this program would be feasible and acceptable in a 
caregiver population of patients with dementia, such as in Alzheimer’s dementia, Parkinson’s 
disease dementia, vascular dementia, or other, has yet to be determined. 
Implications for Clinical Practice 
 The present study provides great promise for the use and potential benefit of the PAL 
program on improving motivation, mood, and perceived quality of life in non-demented PD 
patients.  Given that apathy is one of the most common neuropsychiatric symptoms in PD and 
other disorders involving frontal-subcortical circuitry, occurring in an estimated 40-45% of PD 
patients (Isella et al., 2002; Starkstein et al., 1992a) and that apathy has been associated with a 
wide variety of undesirable factors, including cognitive impairment, poor daily functioning, poor 
treatment compliance and illness outcome, reduced quality of life, and increased caregiver 
burden and distress (e.g., Isella et al., 2002; Pluck and Brown, 2002; Copeland et al., 2003; 
Starkstein et al., 2006; Vicini Chilovi et al., 2009; Starkstein et al., 1993, Resnick et al., 1998, 
Pluck and Brown, 2002, Weintraub, et al., 2004, Velligan et al., 2002, Mayo et al., 2009), 
treatments targeting apathy are particularly important. Behavioral interventions provide a non-
pharmacologic alternative for patients who are frequently on a number of medications already 
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and wish to avoid risking side effect encounters by adding additional medications to their 
regimen.    
 Further, a wealth of research has shown that physical and mental activity engagement are 
strong protective factors for warding off severe cognitive impairment (e.g., Fratiglioni, Paillard-
Borg, & Winblad, 2003; Verghese et al., 2003, 2006; Wilson et al., 2002) and that increased 
physical activity engagement prevents physical deterioration and the onset of other health 
problems in the general population (e.g., Murray & Lopez, 1997; Lopez, Mathers, Ezzati, 
Jamison, & Murray, 2006; Warburton, Nicol, & Breedin, 2006). These findings have also been 
demonstrated in PD populations (e.g., Tanaka et al., 2008; Speelman et al., 2011). PD patients 
are faced with having difficulties with self-generation, making activity initiation even more 
difficult relative to a normal elderly population. They are physically more sedentary than 
controls and this worsens as their disease progresses (van Nimwegan et al., 2011). Given that the 
use of external cues have been demonstrated to help counter the self-generation difficulties that 
PD patients experience in a variety of domains, including gait initiation (e.g., Rubinstein et al., 
2002; Thaut et al., 1996; Burleigh-Jacobs et al., 1997), ocular movements (Winograd-Gurvich et 
al., 2004), and persistence and cognitive processing (e.g., Buytenhuijs et al., 1994; Brown and 
Marsden, 1988), we expect that the structured aspect of the PAL program with the use of a 
calendar, weekly telephone sessions with a supportive Program Coach, and automated iPing calls 
were helpful for increasing and maintaining activity and productivity in this population.  
 The PAL program would be an excellent addition to PD support groups. Several support 
groups are implementing music and exercise programs. The PAL program could be used during 
support group meetings as a method to increase engagement in a number of target activities, 
including physical exercise to improve strength and physical health, vocal exercise to improve 
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vocal strength given that hypophonia is a common symptom in PD, cognitive activity to target 
improvement in cognitive health, and social engagement to improve mood, cognitive 
functioning, and quality of life overall. While we did not implement the program as a group 
activity, we expect that the program might be successful in small groups. It is also possible that 
PD support group members could serve as peer coaches to contact each other weekly once 
individual goals are established at the beginning.  Psychotherapists and mental health counselors 
may find the program useful for PD patients, or other patients struggling with apathy, in 
individual therapy sessions.  
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Appendix: Program Coach Adherence Checklist 
 
TREATMENT ADHERENCE SCALE 
Planning Session 
Date:  
Coach:  
Rater:  
 
RATING KEY:  
 Y = Yes; Coach did not deviate from protocol 
 N = No; Coach deviated from protocol (comment should be noted)  
 CR = Cannot Rate / Not Applicable (comment should be noted) 
 
PLANNNG SESSION:  
Duration: __________ 
 
Rating Item 
 
 
 
Y     N     CR 
Y     N     CR 
 
 
 
Y     N     CR 
 
 
 
 
 
 
 
 
 
 
Y     N     CR 
 
Y     N     CR 
 
 
 
INFORMED CONSENT:  
1. Did the Program Coach (PC) adequately review informed consent? 
2. Did the PC ensure that the participant understands the timeline of the study 
(i.e., 6-week intervention, 3 questionnaires over 12 weeks, weekly phone 
contact with PC, automated reminder calls)? 
3. Did the PC ensure that the participant understands his/her responsibilities 
(i.e., completing questionnaires at appropriate time points, monitoring 
activities daily)? 
 
Comments: _____________________________________________________ 
                   ______________________________________________________ 
 
VERIFICATION OF CONTACT:  
4. Did the PC verify the phone number of the participant and verify the contact 
number for iPing contacts? 
5. Did the PC inform the participant that iPing would call from a 1-866 
number? 
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Y     N     CR 
 
 
 
 
 
 
 
 
Y     N     CR 
 
 
 
 
 
 
 
Y     N     CR 
Y     N     CR 
Y     N     CR 
Y     N     CR 
 
Y     N     CR 
 
Y     N     CR 
 
Y     N     CR 
 
 
 
 
 
 
 
 
 
 
 
Comments: _____________________________________________________ 
                   ______________________________________________________ 
 
SCHEDULING:  
6. Did the PC schedule upcoming iPing phone contacts? 
 
Comments: _____________________________________________________ 
                   ______________________________________________________ 
 
QUESTIONNAIRE COLLECTION:  
7. Did the PC collect the questionnaire AND check for missing data? 
 
Comments: _____________________________________________________ 
                   ______________________________________________________ 
 
BACKGROUND/RATIONALE: Did the PC adequately explain the reason for 
conducting this study by addressing the following points? 
8. PC stated that apathy in PD is common. 
9. PC explained why apathy is relevant to PD patients.  
10. PC provided at least three examples of apathy in PD.  
11. PC provided at least three examples of the negative consequences of 
apathy. 
12. PC stated that apathy can affect the spouse/caregiver. 
13. PC stated purpose of this study.  
14. PC stated that this participant is in the study because they scored high on a 
measure of apathy. 
Comments:______________________________________________________ 
                   ______________________________________________________ 
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Y     N     CR 
 
 
 
 
 
 
 
 
 
 
 
Y     N     CR 
 
 
 
 
 
 
 
 
 
Y     N     CR 
 
Y     N     CR 
 
 
 
 
 
 
 
 
Y     N     CR 
Y     N     CR 
Y     N     CR 
 
Y     N     CR 
Y     N     CR 
 
Y     N     CR 
REVIEW OF THE MANUAL:  
   Unit 1 
15. PC stated that Unit 1 introduces the program and reiterates that they will 
work together through this program to increase activity and goal attainment. 
 
Comments: _____________________________________________________ 
                   ______________________________________________________ 
 
 
   Unit 2 
16. PC stated that Unit 2 provides a rationale for the study, including more 
depth into the theories and strategies that served as the foundation for this 
study, in case the participant wishes to read this at home. 
 
Comments: _____________________________________________________ 
                   ______________________________________________________ 
 
   Unit 3 
17. PC stated the requirements of the participant and spouse as participants in 
the study. 
18. PC reviewed the timeline. 
 
Comments: _____________________________________________________ 
                   ______________________________________________________ 
 
   Unit 4 
19. PC stated the purpose of the baseline evaluation. 
20. PC provided participant with dated questionnaire packets. 
21. PC guided the participant in brainstorming activity ideas using the Life 
Areas Assessment. 
22. PC guided participant in the selection of six target goals. 
23. PC verified that the selected goals range in level of difficulty (two easy, 
two moderate, two difficult). 
24. PC verified aloud that these goals are S-M-A-R-T goals. 
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Y     N     CR 
Y     N     CR 
 
 
Y     N     CR 
 
Y     N     CR 
 
 
Y     N     CR 
Y     N     CR 
 
 
 
Y     N     CR 
 
Y     N     CR 
 
 
Y     N     CR 
 
 
 
 
 
 
 
 
 
Y     N     CR 
 
 
Y     N     CR 
 
 
Y     N     CR 
 
 
Y     N     CR 
 
 
 
Y     N     CR 
 
 
25. PC correctly transferred target goals to the Master Activity Log 
26. PC sufficiently planned the upcoming 6 weeks, incorporating the goal 
hierarchy and titrating engagement across the 6 weeks, using the Master 
Activity Log.  
27. PC presented implementation intention question #1 and obtained a 
response from the participant. 
28. PC presented implementation intention question #2 and obtained a 
response from the participant. 
29. PC  reviewed the 6-week plan with the participant and spouse 
30. PC presented the Weekly Behavioral Checklist for Week One (with first 
week’s goal, frequency, and duration listed) and gave a clear explanation of 
how to use it by circling Y or N and using tick-marks for achieved goals. 
31. PC guided participant through the identification of rewards and verified 
that the participant knows how to use the reward checkboxes 
32. PC reminded participant to have this form with them during all future 
telephone contacts. 
33. PC explained the iPing system, including (i) rationale, (ii) schedule of 
iPing calls, and (iii) call will come from a 1-866 number. 
 
Comments: _____________________________________________________ 
                   ______________________________________________________ 
 
REVIEW:  
34. PC verified that participant knows which activities s/he is targeting this 
week. 
35. PC verified that participant has planned a day and time to initiate the first 
activity (implementation question #1).  
36. PC verified that participant has determined a time of day when s/he will 
record his/her activity accomplishments for each day (e.g., before bed, after 
dinner, after taking evening medications) (implementation question #2).  
37. PC verified that participant knows how to record activity accomplishments 
by circling “Y,” “N,” and marking when activity goals have been met for the 
week.  
 
38. PC verified that participant knows what s/he is supposed to do after placing 
a tick-mark, or check-mark, in the “activity completed” column (Answer: 
Reward!).  
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Y     N     CR 
 
 
Y     N     CR 
 
39. PC reminded the participant that s/he will receive automated reminder calls 
a few times this week from a 1-866 number, to answer this call, and to answer 
“Yes” when asked if the call has been received. 
40. PC reminded the participant when the next scheduled telephone contact 
will occur. 
 
Comments: _____________________________________________________ 
                   ______________________________________________________ 
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TREATMENT ADHERENCE SCALE 
Phone Sessions 
Date:  
Coach:  
Rater:  
 
RATING KEY:  
 Y = Yes; Coach did not deviate from protocol 
 N = No; Coach deviated from protocol (comment should be noted)  
 CR = Cannot Rate / Not Applicable (comment should be noted) 
 
PHONE SESSIONS:  
Duration: __________ 
 
Rating Item 
 
 
Y     N     CR 
 
 
 
 
 
 
 
Y     N     CR 
 
Y     N     CR 
 
Y     N     CR 
 
 
 
Y     N     CR 
 
Y     N     CR 
 
Y     N     CR 
 
 
 
 
 
 
 
GREETING: 
1. PC greeted the participant by introducing him/herself in a friendly manner. 
 
Comments: ______________________________________________________ 
                   ______________________________________________________ 
 
REVIEW OF THE PREVIOUS WEEK: 
2. (If applicable) PC asked if the needed questionnaires have been mailed. 
3. PC recapped the number of goals targeted for the previous week AND named 
each of these goals. 
4. PC recorded the number of accomplished goals in the “Do” column AND 
verified that these are the number of goals reached to completion (i.e., target 
frequency and duration). 
5. PC used praise to reinforce the participant for accomplished goals, and asked 
about and encouraged seeking the planned reward. 
6. PC asked for an explanation on why unachieved goals were not 
accomplished AND asked if the goal may be unrealistic. 
7. PC commented on whether these goals should be adjusted and made 
appropriate adjustments (if applicable). 
 
Comments: ______________________________________________________ 
                   ______________________________________________________ 
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Y     N     CR 
 
Y     N     CR 
 
 
 
Y     N     CR 
 
Y     N     CR 
 
Y     N     CR 
 
 
Y     N     CR 
 
 
 
 
 
 
 
 
 
 
Y     N     CR 
 
 
PLANNING FOR THE WEEK AHEAD: 
8. PC prompted the participant to pull out a blank Behavior Checklist and label 
it appropriately. 
9. PC clearly and accurately (including any changes) stated what the planned 
goals are for the upcoming week, including frequency and duration 
information. 
10. PC verified that the participant understand his/her responsibilities for this 
week.  
11. PC asked the participant if s/he has any questions. 
12. PC reminded the participant that s/he will continue to receive automated 
reminder calls from a 1-866 number, to answer this call, and to answer “Yes” 
when asked if the call has been received. 
13. (If applicable) Did the PC inform the participant that s/he will need to 
complete the appropriate questionnaire packet this week AND state the date by 
which it must be mailed.  
 
Comments: ______________________________________________________ 
                   ______________________________________________________ 
 
CONCLUDE: 
14. PC reminded the participant of the date and time of the next scheduled 
phone contact.  
 
Comments: ______________________________________________________ 
                   ______________________________________________________ 
 
 
 
 
